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1 INTRODUCTION 
1.1 Therapeutic approach for genetic disorders 
Many severe diseases like congenital disorders and various cancer forms can be 
traced back to inaccurate processes on cellular level and are still beyond remedy. 
Therefore, many scientists have dedicated themselves to the quest for finding a cure 
for such disorders. By replacing or interfering with missing and defective genes they 
tackle the problem at its origin.  
Meanwhile, there are several possibilities of approaching this topic. Therapeutic 
DNA, for instance, can be delivered to the nucleus of the target cells so as to replace 
missing or defective genes (Fig. 1). More than thirty years ago, T. Friedmann and R. 
Roblin discussed the at that time controversial issue of treating genetically 
determined disorders with therapeutic DNA [1]. During the last decades vast progress 
has been made in this field and although gene therapy is not an established 
treatment form yet, there are several clinical trials ongoing [2-5]. The spectrum of the 
treated disorders is broad, trying to cure inherited monogenic diseases (e.g. Severe 
combined immunodeficiency (SCID), Leber`s congenital amaurosis (LCA), 
Hemophilia B), infectious diseases (e.g. HIV, Hepatitis C) or cardiovascular 
disorders, to mention but a few examples. Nevertheless, the majority of clinical trials 
address various cancer forms, among others gastrointestinal and prostate tumors or 
cancer of the nervous system, as they occur with a very high prevalence and often 
are fatal.  
Another approach which got in the last twenty years more and more into focus is the 
use of oligonucleotides aiming for specific targets within the cell. Oligonucleotides are 
short fragments of nucleic acids which can fulfill, depending on their nature, various 
tasks, thereby following one aim: regulation of inaccurate processes within the cell. 
Different classes have been evaluated for their therapeutic potential, either taking 
advantage of the antisense technology [6-9], or making use of other short nucleic 
acids such as decoy oligodeoxynucleotides [10], aptamers [11], polyinosine-cytosine 
RNA (polyIC) [12, 13] or antagomirs [14, 15]. 
However, the perhaps best-known oligonucleotide and its applications is small 
interfering RNA (siRNA). Meanwhile, it is more or less general knowledge that 
Andrew Fire and Craig Mello, received the Nobel Prize in 2006 for their work on RNA 
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interference (RNAi) in 1998. They described the impact of exogenous double-
stranded RNA (dsRNA) on specific silencing of genes compared to delivered single 
strands in the nematode Caenorhabditis elegans [16]. Almost equally famous is the 
work of T. Tuschl and colleagues on the application of exogenous synthetic 21-
nucleotide dsRNAs (also: small interfering RNAs; siRNAs) and their capability for 
gene silencing in mammalian cells three years later [17]. The pathway of RNA 
interference (RNAi) with double-stranded siRNA starts in the cytosol with its 
incorporation into the RNA-induced silencing complex (RISC). In the so-called Pre-
RISC complex the `passenger` strand is degraded by an Argonaute (AGO) protein. 
The thus activated RISC contains AGO and the `guide` strand, which can then 
associate with the complementary target messenger RNA (mRNA). Subsequent 
mRNA cleavage leads to suppression of transcription of the corresponding gene (Fig. 
1). Therefore, RNA interference leads to highly sequence-specific and efficient 
posttranscriptional gene silencing of target genes. Since the discovery that this 
pathway can be harnessed for therapeutic purposes, application in humans has 
rapidly advanced towards clinical trials [18, 19].  
 
 
Fig.  1. pDNA and siRNA pathway within the cell.  
pDNA, after entering the cell, is imported into the nucleus, where it leads to gene 
expression. SiRNA, for its part, is incorporated into the Pre-RISC complex, where the 
`passenger` strand is cleaved. The `guide` strand within the activated RISC binds to 
the target mRNA which is subsequently cleaved by the Argonaute (AGO) protein, 
thus leading to gene silencing.  
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1.2 Bottlenecks within nucleic acid delivery 
Although research in the field of nucleic acid delivery is already far advanced, there is 
still need for the optimal delivery system, as the payload encounters several 
obstacles on the way to its site of action. Therefore, nucleic acid delivery to the target 
cell compartment is not an easy task, but as the drawbacks are known, they can be 
targeted for optimization.  
When aiming at systemic administration of the pure therapeutic nucleic acid, reaching 
the target cells within the body undamaged is the major challenge after application. 
Enzymatic degradation during blood circulation by nucleases [20] and rapid renal 
clearance [21] are the first drawbacks which must be overcome. When applied 
locally, passing the anionic barrier cell membrane is an almost insuperable task due 
to electrostatic repulsion of the negatively charged nucleic acid phosphate backbone. 
Furthermore, as the size of both pDNA and siRNA is relatively large, internalization 
by passive diffusion is hampered. Additionally, in contrast to siRNA which acts in the 
cytosol, pDNA has to reach and enter the nucleus in order to allow transcription and 
thus mediate gene expression. A major obstacle within the cell is the transport to the 
nucleus, as the cellular actin cytoskeleton impedes migration of the pDNA towards its 
site of action [22, 23]. Active nuclear import through the nuclear pore complex (NPC) 
is hampered in non-dividing cells for particles lager than approximately 10 nm [24-
26]; proliferating cells allow passive nuclear import during cell division [27, 28]. 
Therefore, the nucleic acid needs an efficient carrier with the ability to condense it to 
an appropriate small particle size, to protect it during blood circulation without 
inducing unspecific interactions with blood components and to mediate cellular 
uptake in target cells without damaging the cell membrane.  
After internalization, the carrier has not completed its task; it has to help the payload 
escape endosomal entrapment. The particles are mostly found in intracellular 
vesicles after cellular uptake, which fuse to early endosomes. The pH within these 
early endosomes drops to 5.9 – 6, whereas maturation takes place by further 
acidification due to ATP-driven proton pumps in the endosomal membrane. As the 
the composition of the intra-endosomal environment cannot facilitate digestion of all 
proteins and lipids, late endosomes undergo fusion with lysosomes. Lysosomes 
contain additional enzymes, including nucleases, which would lead to nucleic acid 
degradation, unless the carrier facilitates endosomal escape before reaching this 
state. Finally, after release into the cytosol, the carrier has to set free its undamaged 
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cargo in or near the desired target cell compartment, namely the nucleus for DNA 
and the cytosol for siRNA. Concerning pDNA, late endosomal escape after 
microtubular transport of the vesicles to the perinuclear region is of advantage [29, 
30], in order to avoid hampered cargo transport within the cell. Fig. 2 shows 
exemplarily the pathway of a polyplex assembled with a cationic polymer containing a 
degradable disulfide linkage and the negatively charged nucleic acid.   
 
 
Fig.  2. Nucleic acid delivery exemplified by using a cationic polymer containing 
degradable disulfide linkages as carrier system. Polyplex formation takes place due 
to electrostatic interactions. After cellular uptake of the polyplex by endocytosis and 
endosomal escape, siRNA is further processed in the cytosol whereas pDNA has to 
enter the nucleus.  
 
1.3 Overcoming the barriers: Nucleic acid carrier 
systems  
1.3.1 Viral vectors 
In search of efficient and biocompatible gene therapy, manifold carrier systems have 
been developed and investigated. However, the ideal carrier was already invented by 
nature – the virus. Due to its natural programming of inserting viral genetic material 
into target cells, it is capable of adapting to differing environmental conditions 
between extra- and intracellular compartments like enzymes, pH or redox potential. 
And indeed, this is the secret of its high efficiency, as it can dynamically change its 
conformation on environmental demand, securely leading the genetic material to its 
biological site of action [31].  
Different viral vector systems have been evaluated during the last decade for gene 
and oligonucleotide delivery, whereas adenoviruses [32],  adeno-associated viruses 
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(AAV) [33] and lentiviruses (LV) [34], a subclass of retroviruses, were the most 
commonly vectors used for gene therapy.  
Gene silencing by taking advantage of the RNAi pathway could be achieved also by 
means of viral vectors [35]. Delivery of siRNA itself has only a transient effect, 
though, as siRNA acts in the cytosol and the amount decreases rapidly during cell 
division. Hence, another strategy was explored, namely the sustained intracellular 
expression of siRNA from plasmid DNA as shRNA, as shown by Brummelkamp et al. 
[9] and Paddison and colleagues [36]. Insertion of cassettes encoding for the 
corresponding shRNA, which are transcribed in the nucleus and further processed in 
the cytosol led to prolonged siRNA expression. 
Nevertheless, there are good reasons why viral gene therapy is still handled with 
caution – the risk for serious host immune response [37], occurrence of mutagenic 
integration [38], limited loading capacity and high production costs still limit clinical 
application [39].  
1.3.2 Non-viral vectors 
In the field of non-viral gene delivery systems, cationic polymers and cationic lipids 
have meanwhile received much attention [40, 41] as they are able to circumvent 
some of the disadvantages associated with viral vectors, e.g. by displaying higher 
biocompatibility as they do not provoke such high immune response [42], higher 
loading capacity and feasibility for large-scale production. Unfortunately, they still 
cannot achieve comparable transfection efficiency. Hence, as such carriers offer 
manifold possibilities for optimization, much effort has been put into increasing the 
therapeutic potential. 
A cationic lipid formulation entrapping DNA for in vitro transfection was first reported 
by Felgner et al. in 1987 [43]. Due to ionic interactions between the positively 
charged lipid head group and the negatively charged DNA, so called “lipoplexes” 
were formed. Since then, cationic lipid formulations for nucleic acid delivery have 
been further developed, even entering clinical trials [44-46].  
In 1962, Smull and Ludwig observed an infection enhancement of eukaryotic tumor 
cells when RNA was mixed with the cationic proteins histone and protamine before 
adding it to cell culture medium [47]. Such complexes formed due to electrostatic 
interactions between a cationic compound and the negatively charged nucleic acid 
were later termed “polyplexes” [48]. The advantage of such interplay between carrier 
and cargo is that the interaction takes place in a non-damaging reversible manner. A 
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further benefit of cationic polymers is that these can be chemically designed and 
produced which leaves room for further specific modifications directed to creating 
non-immunogenic, bioresponsive and dynamically acting molecules. 
Non-adaptable, synthetic cationic polymer-based systems, such as branched and 
linear poly(ethylenimine); PEI, poly(lysine); PLL, dendritic poly(amido amine); 
PAMAM and poly(propylenimine); PPI were already widely evaluated as nucleic acid 
delivery systems. The correlation between transfection efficiency and cytotoxicity has 
been shown to be unsatisfactory though, i.e. effective transfection agents like PEI 
displayed also undesired cytotoxic effects [49, 50].  
Although within the polyplex the nucleic acid should be protected during blood 
circulation, unspecific interactions with blood components and therefore rapid 
clearance from the blood stream [51, 52], unspecific interactions with non-target cells, 
formation of aggregates at physiological salt concentrations [53] and resultant 
cytotoxic effects still can occur. Chemical incorporation of hydrophilic moieties like 
the widely used PEG for electrostatic shielding offers a way to overcome these 
problems. PEGylation shows not only an elongated blood circulation time, but also 
better water solubility and reduced cytotoxicity [54]. Transfection efficiency, however, 
is also reduced [55, 56] due to limited interaction of the shielded positive polymer 
charges with the negatively charged cell membrane. Besides that, PEG shielding 
hampers intracellular release of DNA and siRNA from endosomal vesicles [57, 58]. 
Including targeting ligands in PEGylated polyplexes is one way to enhance 
transfection efficiency as cellular uptake is improved due to receptor-mediated 
endocytosis [59-61]. An additional possibility is to increase the cytosolic release of 
DNA or siRNA by chemically programmed PEG-polymer linkages to be pH-sensitive 
and thus cleavable in the endosome [62-64]. 
Reaching the target tissue after systemic delivery faces an enormous challenge: the 
vascular barrier. Extravasation barriers differ from tissue to tissue. While CNS is 
extremely well protected against extravasating agents by the blood brain barrier, 
hepatocytes, inflammation sites or tumor sites are much more accessible. In the latter 
case the tumor tissue can be achieved either by “passive” or “active” targeting. 
Passive targeting takes advantage of the enhanced permeability and retention (EPR) 
effect [65]. This phenomenon implies polymer accumulation in tumor tissue due to its 
leaky vasculature and deficient lymphatic clearance [66]. 
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Active targeting implies the conjugation of targeting ligands to nucleic acid carrier 
systems which specifically bind to receptors expressed on cell surfaces, as tumor 
cells often show an over-expression of a series of specific receptors. First shown for 
DNA delivery by conjugation of hepatocyte target moiety asialoorosomucoid (ASOR) 
to polylysine over twenty years ago [67], there are various ligands which can be used 
for active targeting, such as transferrin [68], epidermal growth factor (EGF) [30], RGD 
[69, 70] or folic acid [71, 72].  
Once internalized, the essential step for the polyplex is to rapidly escape the 
endosomal vesicle in order to release the nucleic acid in the cytosol and prevent its 
lysosomal degradation. As the endosomal and lysosomal pH presents values 
between 4.5 and 6.5 and therefore differs from the neutral pH of 7.4 in other 
biological compartments [73], this characteristic can be taken advantage of by using 
different strategies.  
Within the class of cationic polymers, polyethylenimine (PEI) has unique favorable 
properties for intracellular nucleic acid delivery. Synthetic variations in both molecular 
weight and structure are possible, also with differing effect on efficiency and 
biocompatibility [74, 75]. PEI has outstanding properties concerning pDNA binding 
ability and buffering capacity for endosomal escape due to the 1,2-diaminoethane 
motif [76-78]. Due to its high charge density [74] it facilitates endosomal escape by 
taking advantage of the so-called “proton sponge effect” [79]. PEI nitrogens are only 
moderately protonated at physiological pH [80], whereas protonation increases upon 
endosomal acidification. Due to proton accumulation within the vesicle and therefore 
high density of positive charge, the influx of chloride and water is increased. Finally, 
the osmotic pressure and membrane destabilization effect of the cationic compound 
leads to endosome disruption and thus to particle release into the cytosol. Current 
investigation on the impact of the length of such moieties containing the 
diaminoethane motif revealed the correlation between amount of protonable amines, 
position within the chain and buffering capacity [81-83].  
The imidazole group within the histidine side chain can be also used as a buffering 
domain. Due to its chemical structure protonation occurs only at an acidic pH value, 
which makes this amino acid interesting for enhancing endosomal escape by the 
proton sponge effect. Therefore, it was often chemically integrated in nucleic acid 
carriers and various research groups could show enhanced transfection efficacy due 
to histidine introduction. Midoux and Monsigny showed first enhanced pDNA 
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transfection of the cationic polymer polylysine modified with histidine residues in 1999 
[84]. Since then, histidine or the imidazole group has been widely used for nucleic 
acid carrier optimization [85-90]. 
Of course, endosomal escape can be further enhanced by introduction of specific 
endosomal membrane disrupting or pore forming domains, such poly(vinyl ether) [91] 
or endosomolytic peptides like melittin or the influenza peptide [92, 93]. Melittin, for 
instance, a peptide from bee venom consisting of 26 amino acids, is able to enhance 
transfection efficiency of polycations [12, 94-97] by damaging interactions with the 
endosomal membrane [98]. As its lytic potential, though, is not pH-selective, various 
modifications led to specific activation of the lytic activity at acidic pH, thus preventing 
cytotoxic side effects before internalization [99-102].  
Efficient gene carriers like linPEI, though, have the disadvantage that, when applied 
in vivo, they cannot be degraded and metabolized by the body and accumulation 
occurs with consequent undesired toxic effects [49, 103]. Therefore, a strategy 
towards uniting appropriate carrier molecular weight, adequate nucleic acid 
condensation and cytosolic release for efficient transfection with low toxicity is the 
design of biodegradable vectors. These are composed of low molecular weight 
(LMW) monomers linked via degradable bonds resulting in a high molecular weight 
(HMW) polymer. Triggered by environmental conditions, these polymers are thus 
chemically programmed to degrade into their LMW non-toxic decomposition 
products.  
There are also different strategies for creating such biodegradable nucleic acid 
carriers. One possibility is to take advantage of the acidic endosomal environment by 
introduction of acid-sensitive linkers [63, 104, 105]. Another option is connecting low 
Mw compounds by hydrolysable linkages, which degrade in a time-dependent 
manner [106-108]. Furthermore, one can take advantage of the redox difference 
between oxidizing extracellular and reducing intracellular environment. Chemically 
incorporated disulfide linkages into polymeric compounds remain therefore relatively 
stable during blood circulation and can then be cleaved in the cytosol by the reducing 
agent glutathione (GSH), the most abundantly occurring thiol-source in mammalian 
cells [109]. Similar to hydrolysable ester-linked polymers, cationic carriers with 
integrated disulfide bonds can decompose into their smaller molecular weight 
compounds and therefore release the nucleic acid in the cytosol with lower 
cytotoxicity than larger non-degradable carriers [110-112]. Polyplex stabilization by 
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introduction of reducible cross-linking agents before [113] or after [114] complexation 
with the nucleic acid has also shown promising results in terms of transfection 
efficiency. This strategy has proven to be even more of advantage also for siRNA 
delivery [115-117], as siRNA differs from pDNA in size and charge, which makes 
polyplex stabilization a more crucial feature. 
Therefore, it has to be distinguished between vectors for pDNA and vectors for 
siRNA delivery. As already mentioned, these cargos differ in size and chemical 
properties i and thus efficient pDNA delivery is not a warrant that the same carrier will 
deliver siRNA in an equally efficient manner.  
Consequently, there is need for better defined delivery systems, so as to allow 
conclusions on structure-activity relationships for the respective nucleic acid and thus 
provide information for concerted optimization. 
1.4 Towards better defined delivery systems 
Chemical programming of polymers has proven to be a crucial tool in mimicking 
virus-like features. Thus, alterations in polymer structure and conformation can be 
correlated to transfection efficiency and cytotoxicity. It has to be considered: the 
better the polymer structure is defined, the more detailed study of structure-activity 
relationships is possible. First approaches towards better defined polymer structure 
with narrow molecular weight distribution have been made by poly(amino ester) [106, 
118] and pseudodendrimer synthesis [119]. An additional advantage of these 
structures is also their biodegradablility, which allows high molecular weights for 
nucleic acid condensation and transfection, but without toxicity, as the carriers 
decompose into small Mw, nontoxic compounds.  
A class of molecules with defined architecture are dendrimers. These are 
characterized by a relatively low polydispersity due to the synthetic process, whereas 
stepwise synthesis can be performed by two different methods, divergent or 
convergent [120-122]. Cationic dendrimers like commercially available 
polyamidoamine (PAMAM) [123-125] or polypropylenimine (PPI) [126, 127] have 
already been investigated as nucleic acid carriers. These studies, however, show that 
there is still room for improvement concerning transfection efficiency and cytotoxicity. 
As the synthetic process allows changing the surface character of the dendrimer by 
introducing specific residues for enhanced gene transfection, several modified 
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poly(amido amine); PAMAM [128-131] and PPI [132-136] based structures were 
investigated for DNA and siRNA transfection.  
 
 
Fig.  3. Nucleic acid carrier systems.  
Schematic structure of an adenovirus, chemical structures of linear PEI and PPI G2.  
 
Lipidoids are also a class of efficient nucleic acid carriers and Akinc et al. showed a 
synthetic method of such compounds suitable for combinatorial chemistry. Thus, 
diverse parallel functionalization and screening of a large lipidoid library allowed fast 
determination of efficient carriers [137]. Further development of a combinatorial 
approach of this nucleic acid carrier class was used for the determination of 
functional group effects on siRNA delivery [138]. 
The group around J.-P. Behr followed another strategy, namely the generation of 
monodisperse nucleic acid delivery systems by monomolecular condensation of 
pDNA with cationic detergents [139-141].  
A further possibility of assembling defined nucleic acid carrier systems which bears 
many advantages is solid-phase peptide synthesis. This synthetic strategy will be 
introduced in the following section. 
1.5 Solid-phase peptide synthesis (SPPS) allows 
assembly of precise, sequence defined nucleic acid 
carriers 
In 1963, R. B. Merrifield published his work on peptide synthesis following a novel 
strategy, namely the use of an insoluble but porous chloromethylated polystyrene 
polymer as a solid support for stepwise amino acid assembly [142]. This synthetic 
method mainly makes use of simple chemical principles: the backbone of amino 
acids contains a carboxylic acid and a primary amine. Activation of the carboxylic 
acid enables reaction with a primary amine, resulting in a stable amide bond (Fig. 4). 
Thus, the chain can be elongated in a controlled manner. Accomplishing this reaction 
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on solid phase has the advantage that excess reagents or by products can be 
discarded by washing steps. After finishing the desired sequence, the product can be 
easily cleaved off the solid support and collected by filtration.  
 
 
Fig.  4. Reaction of a primary amine with an activated carboxylic acid to a stable 
amide bond.  
 
After first difficulties, Merrifield further improved this method himself [143] and since 
then great advance has been made towards optimization of reaction conditions, such 
as development of suitable amino acid side chain protection groups in order to 
prevent undesired side reactions or novel cleavage strategies. Furthermore, 
adequate analytical and purification methods for the products make SPPS a reliable 
synthetic method for sequence-defined, precise structures. Also, novel synthetic 
devices enable using SPPS for combinatorial chemistry, as parallel synthesis of 
multiple sequences is possible either manually or using automatic peptide 
synthesizers. Thus, different structural combinations can be generated at the same 
time. 
Due to its many advantages, SPPS was used during the last decades also for the 
synthesis of precise nucleic acid carriers. 
Dendritic structures, for instance, can be easily generated by the introduction of 
lysines with two primary amines in α- and ε-position as branching points. Using this 
attribute, 25 years ago J. Tam generated in a single solid-phase synthesis multiple 
antigenic peptides (MAPs), based on a lysine core matrix and antigenic peptides of 9 
– 16 amino acids [144]. Pursuing the aim of efficient nucleic acid delivery, other 
dendritic structures containing functional amino acids such as histidines as additional 
buffering domains were synthesized by the group around A. J. Mixson [145-147].  
Due to the advantages of SPPS, also cationic lipid-like structures can be generated. 
Wang et al. created a small library of reversibly polymerizable surfactants using 
combinatorial solid phase synthetic strategy. These vectors contain a protonable 
amino head group, two cysteine residues and two lipophilic tails, exhibiting pH-
sensitive membrane disruption potential. By hence facilitated endosomal escape, the 
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surfactants mediated efficient in vitro luciferase silencing, comparable with the 
effectivity of cationic lipids [148]. 
When thinking of pDNA of siRNA delivery, assembly of poly(amido amines) is an 
interesting and promising approach, as introduction of longer building blocks 
containing the buffering diaminoethane motif enhance nucleic acid binding and 
endosomal escape. Only few reports were published on the application of the SPPS 
methodology for the synthesis of shorter poly(amido amines), those also without 
aiming at nucleic acid delivery [149-151].  
In 2006, Hartmann et al. designed linear peptidomimetic polymers with poly(amido 
amine; PAA) as a structural pattern. Dicarboxylates and diamines were stepwise 
coupled in an alternating manner, thus generating a monodisperse oligopeptide. By 
exact introduction of functionalities in the linear PAA chain, such as poly(ethylene 
oxide); PEO, a single component block copolymer was synthesized, thus proving the 
versatility of the method [152]. PEO modified PAAs were studied in a subsequent 
work concerning dsDNA complexation and condensation qualities, resulting in clearly 
defined, non cytotoxic polyplexes [153]. The researcher in their studies applied only 
rather simple diamine compounds and did not include diaminoethane motifs.  
In our laboratory David Schaffert introduced oligoamine building blocks containing 
the buffering diaminoethane unit. In order to avoid undesired side reactions such as 
on-resin crosslinking, Schaffert et al. modified the diaminoethane unit containing 
polyamines with a carboxylic anchor and adequate protection groups, thus making 
them feasible for solid-phase synthesis. By the means of these artificial oligoamino 
acids, precise, sequence-defined oligomers could be assembled [154]. In a 
subsequent publication, cationic oligomers with different topologies and 
modifications, such as introduction of cysteines and/or lipophilic domains, were 
designed, showing efficient transfection results for both pDNA and siRNA delivery 
and allowing conclusion on structure-activity relationships [155].  
1.6 Aims of the thesis 
In the current thesis, SPPS had to be used for overcoming the drawback of polymer 
polydispersity combined with maintaining important carrier features such as higher 
molecular weight, cargo binding properties and the buffering diaminoethane motif. In 
particular, the SPPS methodology should be used for the design of branched 
Introduction 17 
oligomers, which are supposed to be biocompatible and sequence-defined, using 
cationic artificial and natural amino acids.  
Firstly, branched structures had to be generated directly on solid support by 
introduction of two subsequent lysines. Due to two primary amines in α- and ε- 
position of lysine, the generated four amino- groups should act as starting points for 
four arms which could be elongated in a parallel manner, allowing gain in molecular 
weight in only few synthetic steps (Fig. 5. A, C, D). Also, the impact of stepwise 
increase of arm length on cargo binding and delivery should be evaluated. Further 
modifications of this class of oligomers like the introduction of cysteines for polyplex 
stabilization, variation in building block length or insertion of histidines as additional 
buffering domain should bring further insights in structure-activity relationships. The 
thus generated compounds had to be evaluated not only for their potential for 
efficient and safe gene delivery, but also for siRNA-mediated gene silencing, so as to 
determine differences in carrier requirements for the respective nucleic acid.  
 
 
Fig.  5. Solid-phase supported synthesis (SPS) of sequence-defined oligomers. 
A preloaded resin (A) can be further modified in a stepwise manner so as to generate 
either linear (B) or, by introduction of lysines, branched (C) oligomers. After finishing 
the desired sequence, the oligomer is cleaved from the solid support (D).  
 
Secondly, a novel approach towards avoiding toxicity related to higher molecular 
weight should be also developed, namely assembly of defined biodegradable 
oligomers for gene delivery. This class of pDNA carriers should consist of the 
structurally defined dendritic core polypropylenimine with eight primary amines on the 
surface (PPI G2), which is non-toxic but also does not mediate transfection efficiency. 
This PPI core had to be modified in so far as to allow linkage of precise, sequence-
defined cysteine-containing oligo(ethane amino)amides (Fig. 5 A, B, D) via disulfide 
bond formation. The disulfide linkages can be cleaved in the reducing cytosolic 
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environment, hence allowing the carrier to decompose into its non-toxic, low Mw 
compounds. 
Therefore, due to the sequence control allowed by SPPS and also by the concerted 
coupling in solution to the PPI core, due to reliable purification and analytical 
methods, two strategies should be followed for the generation of branched, precise, 
biocompatible nucleic acid carriers.  
The final aim of this thesis is, beyond synthesis of the above mentioned compounds, 
to gain interesting new insights on structure-activity relationships concerning pDNA 
and siRNA delivery by biophysical and biological evaluation.  
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2 MATERIALS AND METHODS 
2.1 Chemicals and reagents 
Fmoc-Ala-Wang resin Low Load was purchased from Novabiochem (Darmstadt, 
Germany); pentafluorophenol (Pfp), dicyclohexylcarbodiimide (DCC), 0.5 M tris(2-
carboxyethyl)phosphine (TCEP), 2-chloro-1-methylpyridinium iodide (CMPI), (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT), 1-hydroxy-benzotriazol 
(HOBt), triisopropylsilane (TIS), Triton X-100, 2-(N-morpholino)ethanesulfonic acid 
(MES) and 50mM sodium hydroxide solution from Sigma-Aldrich (Munich, Germany); 
benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) 
and microreactors from MultiSynTech (Witten, Germany).  
All amino acids, peptide grade dimethylformamide (DMF), diisopropylethylamine 
(DIPEA) and trifluoroacetic acid (TFA) were obtained from Iris Biotech (Marktredwitz, 
Germany). Boc-Cys(NPys)-OH (BCNP) was purchased from Bachem (Bubendorf, 
Switzerland). Polypropylenimine (PPI) G2 was obtained from SyMO-Chem 
(Eindhoven, The Netherlands).  
Spectra/Por dialysis membranes were purchased from Carl Roth GmbH (Karlsruhe, 
Germany). 
Linear PEI (linPEI with an average molecular weight of 22kDa) is described in [13]. 
Plasmid pEGFPLuc (encoding a fusion of enhanced green fluorescent protein EGFP 
and Photinus pyralis luciferase under control of the CMV promoter) was produced 
with the Qiagen Plasmid Giga Kit (Qiagen, Hilden, Germany) according to the 
manufacturer specifications.  
Ready to use siRNA duplexes were synthesized and provided by Axolabs GmbH 
(formerly: Roche Kulmbach, Germany): GFP-siRNA (sense: 5'-
AuAucAuGGccGAcAAGcAdTsdT-3'; antisense: 5'-
UGCUUGUCGGCcAUGAuAUdTsdT-3'; small letters: 2’methoxy-RNA; s: 
phosphorothioate) for silencing of the eGFPLuc protein and control-siRNA (sense: 5’-
AuGuAuuGGccuGuAuuAGdTsdT-3’; antisense 5‘-CuAAuAcAGGCcAAuAcAUdTsdT-
3‘) as a control. 
Water was used as purified, deionized water. 
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2.2 General methods for SPPS-based oligomer synthesis 
2.2.1 Syntheses of cationic building blocks 
Cationic building block Stp was synthesized as described in [154]. Gtt was used as 
described and synthesized by Dr. Naresh Badgujar (Wagner lab) in [154]. New 
cationic building block Sph was developed and synthesized by Dr. Naresh Badgujar 
as described in [156]. 
2.2.2 General methods for oligomers synthesis by manual SPPS 
Synthetic step Reagent Reaction time Wash 
Resin swelling 
DMF1 
DMF + 1% 
Triton-X 1002 
11-162 h 
 
1 x DMF1 (+1% 
Triton-X 1002) 
Coupling 
DMF1 (+ 1% 
Triton-X 1002) 1-2 h 
4 x DMF1 (+ 1% 
Titon-X 1002) 
Fmoc 
deprotection 
20% piperidine 
in DMF1 
2% piperidine, 
2% DBU in DMF 
+ 1% Triton2 
1 x 10, 1 x 20 
min1 
6 x 5 min2 
8 x 5 min3 
6 x DMF1 
6 x DMF + 1% 
Triton-X 1002 
Cleavage 
TFA: water 95:54 
TFA:TIS:water 
95:2.5:2.55 
TFA:TIS:water 
92.5:5:2.53 
1-2 h 
2 x TFA 
2 x DCM 
1
 for generation of four-arm core / five-arm Stp tail and subsequent branching /  
linear oligomer 
2
 for synthesis after four-arm branching 
3
 for histidine-containing oligomers 
4
 for not cysteine-containing oligomers 
5
 for cysteine-containing oligomers 
2.2.3 DMF test on amine impurities 
6 µl of a bromophenol blue stock solution (5 mg/ml in DMSO) were added to 1 ml 
DMF. DMF was accepted for use if the solution color was yellow or slightly green.  
Materials and Methods 21 
2.2.4 Fmoc quantification 
5 – 10 mg of dry resin was weighed in duplicates in Eppendorf tubes and agitated 
with 1.0 ml 20% piperidine in DMF for 1.5 h. Thereafter, the tube was vortexed briefly 
and the resin was allowed to settle for approximately 2 min. 25 µl of the supernatant 
of each sample, of a positive control (Fmoc-Ala-Wang resin) and of a blank solution 
(20% piperidine in DMF) were diluted to 1 ml with DMF. A301 of each sample was 
determined in duplicates. The Fmoc-substitution (FS) of the resin was calculated 
using following equation: 
 
FS (mmol/g) =  
 
A301: absorbance at λ = 301 nm 
m: resin mass [mg] 
7800: molar extinction coefficient [L mol-1 cm-1] 
D: dilution factor (0.025) 
2.2.5 Kaiser Test 
Reagent A: 5% ninhydrin in ethanol (w/v) 
Reagent B: 80% phenol in ethanol (w/v) 
Reagent C: 2 ml 0.001 M KCN in 98 ml pyridine 
A few resin beads were taken into an Eppendorf cap and washed three times with 
DMF and three times with methanol. Two drops of each reagent were added and the 
beads were heated at 99°C for 4 min. The presence of free amino groups gave a 
positive test (blue beads), whereas a negative outcome indicated no presence of free 
amino groups (colorless beads).  
2.2.6 Introduction of Triton X-100 
In order to avoid intramolecular chain aggregation due to hydrophobic interactions 
and yield improvement, 1% Triton X-100 was added to the coupling solvent or 
deprotection solvent mixture used for chain elongation of four- and five-arm 
oligomers after branching. 
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2.3 Syntheses of four- and five-arm oligomers 
2.3.1 Synthesis of four-arm core 
After swelling 0.2 mmol of Fmoc-Ala-Wang resin Low Load (Novabiochem) in DMF 
and cleavage of the Fmoc protecting group by double treatment with 20% piperidine 
in DMF, a solution of Fmoc-Lys(Fmoc)-OH (0.4 eq), PyBOP/HOBt (0.4 eq) and 
DIPEA (0.8 eq) in DMF was added to the resin and the vessel was agitated for 1 h. 
The unreacted amino groups were subsequently acetylated using 20 equivalents of 
acetic anhydride and 40 equivalents of DIPEA in DMF before removal of the Fmoc 
protecting group. The second coupling was performed by adding a solution of Fmoc-
Lys(Fmoc)-OH (4 eq), DIPEA (8 eq) and PyBOP/ HOBt (4 eq) in DMF and incubation 
for 1 h. Reaction progress was monitored by Kaiser test. After completion of the 
reaction the resin was washed five times with DMF and five times with DCM and 
dried for 12 h in vacuo. The loading of the resin was determined by 
spectrophotometric Fmoc-quantification using 20% piperidine in DMF. 
2.3.2 Synthesis of four-arm Stp oligomers 
The preloaded resin (0.02-0.04 mmol according to Fmoc loading) was swollen over 
night in DMF. After the swelling 1% Triton X-100 was added to the DMF for use, and 
all subsequent steps including washing, coupling and Fmoc-deprotection were 
performed using this mixture. Fmoc protecting groups were cleaved by six-fold 
treatment (each 5 min) with 2% piperidine, 2% DBU in DMF/Triton. After washing the 
resin, a solution of Fmoc-Stp-OH (4 eq), DIPEA (8 eq) and PyBOP/ HOBt (4 eq) in 
DMF/Triton was added for 90 min. The reaction solvent was drained and the resin 
was washed five times with DMF. Reaction progress was monitored by Kaiser test. 
The whole process was repeated depending on the desired sequence. The resin was 
treated six times (each 5 min) with 2% piperidine, 2% DBU in DMF/Triton in order to 
deprotect the Fmoc group. The resin was washed five times with DMF and five times 
with DCM and dried over KOH in vacuo. For cleavage the resin was suspended in a 
solution of TFA/H2O (95/5, v/v) and agitated for 3 h. The cleavage solution was 
drained and collected. The resin was washed twice with TFA and twice with DCM. 
The collected solutions were concentrated under reduced pressure to minimum 
volume. The residue was washed twice with ice-cold MTBE, then dissolved in water 
and lyophilized. The lyophilized product was dissolved in a minimal volume 10mM 
HCl and dialyzed against 10 mM HCl using a Spectra/Por® Dialysis Membrane, 
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MWCO 3500 Da. After 16 h the buffer was exchanged and the dialysis proceeded for 
another 8 h. The sample was lyophilized and characterized via cation exchange 
chromatography.  
2.3.3 Synthesis of terminally modified four-arm Stp, Gtt and Sph 
oligomers 
Oligomers were synthesized as described above. Additionally, depending on the 
sequence, either Boc-Cys(Trt)-OH or Boc-Ala-OH was coupled as last amino acid in 
the same manner. For cleavage the resin was suspended in a solution of 
TFA/TIS/H2O (95:2.5:2.5, v/v/v) for cysteine containing oligomers, or TFA/H2O (95:5, 
v/v) for alanine containing oligomers, and agitated for 2 h. The cleavage solution was 
drained and collected. The resin was washed twice with TFA and twice with DCM. 
The collected solutions were concentrated under reduced pressure to approximately 
2 ml. The product was precipitated in a 1:1 mixture (40 ml) of cooled (0 °C) MTBE 
and n-hexane and centrifuged at 4 °C for 5 min (3000 rpm). The pellet was then 
dissolved in 10mM HCl containing 30% acetonitrile and purified by size exclusion 
chromatography (SEC). Product fractions were pooled and freeze dried. Identity was 
confirmed by 1H-NMR. Purity of selected oligomers was determined by RP-HPLC. 
2.3.4 Synthesis of five-arm Stp oligomers 
After swelling 0.1 mmol of Fmoc-Ala-Wang resin Low Load (Novabiochem) in DMF 
and cleavage of the Fmoc protecting group by double treatment with 20% piperidine 
in DMF, a solution of Fmoc-Stp-OH (0.5 eq), PyBOP/HOBt (0.5 eq) and DIPEA (1.0 
eq) in DMF was added to the resin and the vessel was agitated for 1 h. The 
unreacted amino groups were subsequently acetylated using 20 equivalents of acetic 
anhydride and 40 equivalents of DIPEA in DMF. Reaction progress was monitored by 
Kaiser test. After completion of the reaction the resin was washed five times with 
DMF and five times with DCM and dried for 12 h in vacuo. The loading of the resin 
was determined by spectrophotometric Fmoc-quantification using 20% piperidine in 
DMF.  
The preloaded resin (0.01 mmol) was swollen in DMF for 1 h. After cleavage of the 
Fmoc protecting group by double treatment with 20% piperidine in DMF, a solution of 
Fmoc-Stp-OH (4 eq), PyBOP/HOBt (4 eq) and DIPEA (8 eq) in DMF was added to 
the resin and incubated for 1 h. In the next two coupling steps Fmoc-Lys(Fmoc)-OH 
was used as described above, 4 eq for the first coupling and 8 eq for the second. 
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After removal of the Fmoc protection group with 20% piperidine in DMF the synthesis 
was carried on according to synthesis of four-arm oligomers, using 16 eq building 
block and amino acid, 16 eq HOBt/PyBop and 32 eq DIPEA in each coupling step. In 
the last coupling step Boc-Cys(Trt)-OH was used. Cleavage from the resin and 
further purification was performed as described above.  
2.3.5 Synthesis of histidine-containing four-arm oligomers 
Oligomers were synthesized as described above, with following modifications: Fmoc-
His(Trt)-OH was used as additional amino acid. Fmoc-deprotection cycles were 
increased to eight times five minutes. Cleavage from the resin was performed with 
TFA/TIS/H2O (92.5/5/2.5, v/v/v). 
Compounds 582 and 584 (based on [146]) were synthesized automatically using a 
SyroWAVE Peptide synthesizer (Biotage Sweden AB, Uppsala, Sweden). Couplings 
were performed 2 x 5 min using a microwave device, deprotection steps were 
performed using 20%piperidine, 2% DBU in DMF for 3 x 20 min. Cleavage,  
purification and characterization was performed as described above.   
Synthetic methods for the generation of polypropylenimine (PPI) conjugates 
2.3.6 Synthesis of linear Stp oligomers 
A Fmoc-Cys(Trt)-Wang resin was preswollen in DMF for 1 h. Fmoc-deprotection was 
performed by double treatment with 20% piperidine in DMF. After washing the resin 
five times with DMF, a solution of Fmoc-Stp-OH (4 eq), PyBOP/HOBt (4 eq) and 
DIPEA (8 eq) in DMF was added to the resin and the vessel was agitated for 1 h. 
Reaction progress was monitored by Kaiser test. The procedure was repeated, 
depending on the sequence, up to four times. After the last Fmoc-deprotection the 
resin was washed five times with DMF, five times with DCM and dried over night in 
vacuo. Cleavage from the resin was performed by treatment with TFA/TIS/H2O 
(92.5/2.5/2.5, v/v/v) for two hours. The cleavage solution was then drained and 
collected; the resin was washed twice with TFA and twice with DCM. The collected 
solutions were concentrated to approximately 1 ml and precipitated in ice-cold 
MTBE/n-hexane (1/1). After centrifugation, the pellet was rewashed with ice-cold 
MTBE. The product was then dissolved in water and freeze dried. Identity was 
confirmed by 1H-NMR. 
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2.3.7 Synthesis of Boc-Cys(NPys)-pentafluorophenyl ester   
(BCNP-OPfp) 
BCNP-OPfp was synthesized according to [157] with slight modifications. 500 mg 
Boc-Cys(NPys)-OH (1.33 mmol) and 269.3 mg pentafluorophenol (Pfp, 1.463 mmol, 
1.1 eq) were suspended in 5 ml DCM. 1 eq dicyclohexylcarbodiimide (DCC, 274.4 
mg) was dissolved in 1 ml DCM and added to the solution. The mixture was stirred 
for 15 min at 0°C and subsequently for 3.5 h at room temperature. After cooling the 
solution to 0°C, precipitated dicyclohexylurea (DCU) was filtered and the solvent 
evaporated. Completion of the reaction was monitored by TLC (Rf in ethylacetate: 
BCNP: 0; Pfp: 0.6, sample: 0.8; in chloroform/methanol 3:1: BCNP: 0.2, Pfp: 0.8, 
sample: 0.9).  
Yield: 650 mg (90%) 
2.3.8 Synthesis of activated PPI core (PPI-CNP) 
30 mg PPI G2 (0.039 mmol) was dissolved in 1 ml DCM. 588.4 mg Boc-Cys(NPys)-
OPfp (28 eq, 1.087 mmol) was dissolved in 5 ml DCM and added to the PPI solution. 
The mixture was stirred for 24 h at room temperature. The solvent was concentrated 
to a minimal volume and precipitated in ice-cold MTBE. After centrifugation and 
decantation of the supernatant, the residue was washed with ice-cold MTBE and the 
procedure repeated until the washing solution was colourless. The residue was then 
dissolved in acetonitrile, freeze dried and analyzed by 1H-NMR. 
Yield: 108 mg (46%) 
1H-NMR: δ (ppm) = 1.4-1.5 (s, 72 H, -CH3 boc), 1.6-1.7 (m, 28 H, -CH2-CH2-CH2- 
PPI), 2.4-3.3 (m, 68 H, βH cysteine, PPI), 4.3 (t, 8 H, αH cysteine), 7.5 (dd, 8 H, 
J=4.7, 8.3 Hz, -CH=CHNPys-CH=), 8.6 (dd, 8 H, J=1.6, 8.2 Hz, -CHNPys-C(NO2)=), 8.9 
(dd, 8 H, J=1.5, 4.7 Hz, -CHNPys=N-) 
3.3 (s, MeOD), 4.9 (s, H2O) 
In order to remove the boc protection group the precipitate was dissolved in 1 ml 80% 
TFA in DCM. After 2 h the solvent was evaporated, the residue was dissolved in 
water and freeze dried. The product was subsequently analyzed by 1H-NMR to 
ensure complete boc removal and for quantification of the NPys-groups.  Additionally, 
surface modification was quantified spectrophotometrically. Purity was determined by 
RP-HPLC.  
1H-NMR: δ (ppm) = 1.6-2.4 (m, 28 H, -CH2-CH2-CH2- PPI), 3.1-3.6 (m, 68 H, βH 
cysteine, PPI), 4.2 (t, 8 H, αH cysteine), 7.5 (dd, 8 H, J=4.7, 8.3 Hz, -CH=CHNPys-
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CH=), 8.5 (dd, 8 H, J=1.6, 8.2 Hz, -CHNPys-C(NO2)=), 8.7 (dd, 8 H, J=1.5, 4.7 Hz, -
CHNPys=N-), 4.8 (s, HDO) 
2.3.9 Assembly of PPI conjugates 
PPI-CNP was reacted with 24 eq of linear cationic polymer (related to SH-groups) in 
a minimal amount of reaction buffer (MES pH 6.1 + 20% acetonitrile). After 4 h the 
amount of released nitropyridinethione was measured spectrophotometrically. After 
completion of reaction the sample was transferred to a dialysis tube with an adequate 
MWCO and dialyzed in water pH 5.5 (acetic acid) for 4 h. After buffer exchange 
dialysis was continued for additional 20 h. The sample was then freeze dried and 
analyzed by 1H-NMR.  
2.4 Methods and devices for compound purification and 
chemical characterization 
2.4.1 Dialysis 
Dialysis was performed using SpectraPor tubes of an adequate MWCO. Dialysis was 
performed in water for four-arm Stp oligomers and in water pH 5.5 for PPI conjugates 
at 4°C with buffer exchange after 4 h and total dialysis time of 24 h.  
2.4.2 Size exclusion chromatography 
Size exclusion chromatography of all polymers was run on an Äkta Basic HPLC 
system using a self-packed Sephadex G-10 column (GE Healthcare). The buffer 
used was 10 mM HCl + 30% acetonitrile at a flow rate of 2 ml/min and isocratic 
elution. The product fractions were pooled and freeze dried.  
2.4.3 Analytical ion exchange chromatography (IEX-HPLC) 
Analytical IEX-HPLC was performed using an ÄKTA Basic system (GE Healthcare) 
and a Resource S 1 mL column. Buffer A: 10 mM HCl. Buffer B: 10 mM HCl + 3 M 
NaCl. Flow rate 2 ml/min. Gradient: 2% B to 100% B in 15 min. UV detection at 214 
nm and 280 nm. 
2.4.4 Analytical reversed phase HPLC (RP-HPLC) 
Analytical RP-HPLC was performed using a Waters HPLC System containing a P-
900 gradien pump system under the control of the Millenium software and a C18-RP 
analytical column (Waters SunFire C18, 4.6 x 150 mm). Buffer A: H2O + 0.1% TFA, 
Materials and Methods 27 
buffer B: acetonitrile + 0.1 % TFA at a flow rate of 1 ml/min. The gradient was run 
from 5% to 100% buffer B in 20 min. Absorption of the amide bond was monitored at 
λ = 214 nm with a 996 Photodiode array detector.  
2.4.5 1H-NMR 
1H NMR spectra were recorded using a Jeol JNMR-GX 400 (400 MHz) or JNMR-GX 
500 (500 MHz) device. Chemical shifts are reported in ppm and refer to the solvent 
as internal standard. Data are reported as s=singlet, d=doublet, t=triplet, m=multiplet; 
integration was performed manually. The spectra were analyzed using NUTS (2 D 
professional version 20020107 by Acron NMR, 2002) or MestreNova (Ver. 5.2.5-
4119 by MestReLab Research).  
2.4.6 Mass Spectrometry  
MALDI-MS analysis was carried out on a Bruker Autoflex MALDI-TOF system. 
2.4.7 3-Nitro-2-pyridinesulfenyl (NPys) quantification 
A standard Boc-Cys(NPys)-OH (BCNP) solution was serially diluted in methanol and 
measured spectrophotometrically at 340 nm. The sample was diluted accordingly and 
measured against methanol as a blank. Concentration of NPys was calculated via the 
calibration curve.  
2.4.8 Quantification of 3-Nitro-pyridine-2-thione (NPythione) 
For the calibration curve, a standard BCNP solution was serially diluted in MES 
buffer:acetonitrile 4:1 and measured spectrophotometrically at 440 nm. 
Subsequently, the dilutions were treated with 4 µl TCEP (500 µmol/ml) each and 
incubated at room temperature for 30 min. The released NPythione was measured at 
440 nm against the buffer mixture as a blank. The sample was diluted and treated 
accordingly. Concentration of the released NPythione was calculated after 
subtraction of the absorption values of untreated BCNP via the calibration curve.  
2.4.9 Ellman`s assay [158] 
The colorimetric reaction between Ellman's reagent (5,5'-dithiobis(2-
nitrobenzoicacid), DTNB) and the free thiol groups was performed as follows: 0.4 mg 
DTNB dissolved in 1 ml of Ellman´s buffer (0.2 M Na2HPO4 with 1 mM EDTA at pH 
8.0) was used as stock solution. Standard cystein solution and samples were serially 
diluted in Ellman’s buffer and 10% (v/v) of the stock solution. After 20 minutes 
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incubation at 37 °C the solutions were measured at 412 nm. Ellman´s stock diluted 
1:10 in Ellman´s buffer was taken as blank. Concentration of the thiol group was 
calculated via the calibration curve. 
2.4.10 Tris(2-carboxyethyl)phosphine (TCEP) assay 
A standard cysteine solution (0.05 µmol/ml) was serially diluted with Ellman`s buffer 
and incubated with 40 µl TCEP (5 µmol/ml) for 10 min at room temperature. 
Subsequently, 10 µl 2-chloro-1-methylpyridinium iodide (CMPI, 100 µmol/ml) were 
added and further incubated for 10 min at 37°C. Absorbance was measured at 314 
nm with buffer/TCEP/CMPI mixture as a blank. Concentration of reduced disulfide 
bonds and resulting free thiols was calculated via the calibration curve. 
2.5 Biophysical and biological characterization 
2.5.1 Acidimetric titrations of histidine containing oligomers 
The protonation behaviour was investigated over a pH range of pH 2 to 11. The 
titrations were carried out with an automated potentiometric titrator Metrohm Titrando 
905 equipped with a Biotrode pH electrode (METROHM GmbH & Co. KG, 
Filderstadt, Germany). The oligomer amount corresponding to 15 µmoles protonable 
amines was dissolved in 3.5 ml 50 mM sodium chloride solution. The pH was 
adjusted < 2 with 0.5 M hydrochloric acid. Titrations were carried out with 50 mM 
sodium hydroxide solution until the endpoint of pH 11 was reached. To distinguish 
polymer and solvent effects a control titration of 50 mM sodium chloride solution 
without polymer was performed. Volume differences (∆V) from pH 2 to 11 and pH 5.5 
to 7.4 (endosomal pH range) were determined. 
Buffer capacity was calculated according to the following formula: 
 
    
2.5.2 Polyplex formation 
Polyplex formulations for transfection and binding assay experiments were prepared 
as follows: 200 ng of DNA or 500 ng of siRNA and the corresponding amount of 
polymer were diluted in separate tubes in 10 µL of 20 mM HEPES buffered 5% 
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glucose pH 7.4 (HBG) each. The polycation solution was added to the nucleic acid, 
mixed and incubated for 30-40 min at room temperature.  
2.5.3 Measurement of particle size and zeta potential 
Particle size and zeta potential of pDNA and siRNA formulations were measured by 
laser-light scattering using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, U.K.). PDNA and siRNA polyplexes were prepared in HBG pH 7.4, 
whereas siRNA polyplexes were diluted in 20 mM HEPES prior to measurement. 
2.5.4 pDNA binding assay 
A 1% agarose gel was prepared by dissolving agarose in TBE buffer (trizma base 
10.8 g, boric acid 5.5 g, disodium EDTA 0.75 g, and 1 l of water) and boiling it up to 
100 °C. After cooling down to about 50 °C and addition of GelRed, the agarose gel 
was casted in the electrophoresis unit. Polyplexes containing 200 ng of pDNA in 20 
µL HBG and loading buffer (prepared from 6 ml of glycerine, 1.2 ml of 0.5 M EDTA, 
2.8 ml of H2O, 0.02 g of bromophenol blue) were placed into the sample pockets. 
Electrophoresis was performed at 80 V for 80 min. 
2.5.5 siRNA binding assay 
A 2.5% agarose gel was prepared containing GelRed as described above. 
Polyplexes containing 500 ng of siRNA in 20 µl HBG and loading buffer (containing 
xylene cyanol) were placed into the sample pockets. Electrophoresis was performed 
at 80 V for 40 min. 
2.5.6 pDNA polyplex dissociation assay 
An agarose gel was prepared as for pDNA binding assay. Polyplexes were formed 
and incubated for further 30 min with 0.1, 0.2 and 0.4 I.U. heparin, with TCEP (0.5 M, 
0.5 µl) and with 0.2 I.U. heparin and TCEP. Electrophoresis was run as described 
above. 
2.5.7 Ethidium bromide exclusion assay 
Polymer ability to bind pDNA and siRNA was evaluated by an ethidium bromide 
(EtBr) exclusion assay. The effect of stepwise addition of polymer solution to 10 µg 
pDNA or siRNA in 1 ml HBG containing 0.4 µg EtBr was measured at increasing N/P 
ratios using a Cary Eclipse spectrophotometer (Varian, Germany). Maximal 
Materials and Methods 30 
fluorescence intensity was set 100% for the EtBr solution containing free nucleic acid 
and fluorescence decrease was measured after each addition of polymer aliquot.  
2.6 Cell culture  
Mouse neuroblastoma cells Neuro2A and Neuro2A/EGFPLuc cells, stably expressing 
the CMV‐EGFPLuc cassette (Clontech) encoding a fusion of enhanced green 
fluorescent protein and GL3 firefly luciferase under the control of the CMV promoter 
as described in [159], were grown in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% FCS, 4 mM stable glutamine, 100 U/mL penicillin and 100 
?g/mL streptomycin. 
2.6.1 Luciferase reporter gene expression 
Neuro2A cells were seeded 24 h prior to pDNA delivery using 10000 cells per well in 
96-well plates. In vitro transfection efficiency of the polymers was evaluated using 
200 ng pEGFPLuc encoding plasmid per well. All experiments were performed in 
quintuplicates. Before transfection, medium was replaced with 80 ?L fresh medium 
containing 10% FCS. Polyplexes formed at different protonable nitrogen/phosphate 
(N/P) ratios in 20 ?L HBG were added to each well and incubated at 37 °C. At 24 h 
after  transfection, cells were treated with 100 ?L cell lysis buffer (25 mM Tris, pH 7.8, 
2 mM EDTA, 2 mM DTT, 10% glycerol, 1% Triton X-100). Luciferase activity in the 
cell lysate was measured using a luciferase assay kit (100 ?L Luciferase Assay 
buffer, Promega, Mannheim, Germany) and a Lumat LB9507 luminometer (Berthold, 
Bad Wildbad, Germany). 
2.6.2 Cell viability assay (MTT assay) 
Neuro2A cells were seeded into 96-well plates at a density of 1 × 104 cells/well. After 
24 h, culture medium was replaced with 80 ?L fresh growth medium containing 10% 
FCS and transfection complexes (20 ?L in HBG) at different N/P ratios were added. 
All studies were performed in quintuplicates. 24 h post transfection, 10 µl MTT (5 
mg/ml) were added to each well reaching a final concentration of 0.5 mg MTT/mL. 
After an incubation time of 2 h, unreacted dye and medium were removed. Optical 
absorbance was determined at 590 nm (reference wavelength 630 nm) using a micro 
plate reader (Spectrafluor Plus, Tecan Austria GmbH). 
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2.6.3 Luciferase gene silencing 
Gene silencing experiments were performed in Neuro2A/EGFPLuc cells stably 
expressing the CMV‐EGFPLuc cassette (Clontech) encoding a fusion of enhanced 
green fluorescent protein and GL3 firefly luciferase under the control of the CMV 
promoter as described in [159] The cells were grown as described above. For 
transfection either GFP-siRNA for silencing of the EGFPLuc protein, or control-siRNA 
as a control were used at a concentration of 0.5µg/well each. SiRNA delivery was 
performed in 96-well plates with 5000 cells per well in triplicates. Cells were seeded 
24 h prior to transfection and then medium was replaced with 80 ?L fresh growth 
medium containing 10% FCS. Transfection complexes for siRNA delivery (20 ?L 
formed in HBG) at different N/P ratios were added to each well and incubated at 37 
°C. At 48 h after transfection, luciferase activity was determined as described above. 
The relative light units (RLU) were presented as percentage of the luciferase gene 
expression obtained with only buffer treated control cells. 
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3 RESULTS 
3.1 Four- and five-arm oligo(ethanamino)amides for 
pDNA and siRNA delivery 
3.1.1 Introduction 
Linear PEI with an average molecular weight of 22kDa is often termed the `gold 
standard` for gene delivery. It has outstanding properties concerning pDNA binding 
and transfection [76] not only due to its chemical structure containing the `proton 
sponge` 1,2-diaminoethane motif [77], but also due to its high molecular weight. 
Nevertheless, its polydispersity hampers precise conclusions on structure-activity 
relationships.   
In order to overcome this drawback, SPPS was used as synthetic tool for the 
generation of precise branched oligomers. Lysine, due to two primary amines per 
amino acid in α- and ε- positon, offers the possibility for assembly of branched 
structures (Scheme 1). By subsequent coupling of two 
lysines, four arms can be elongated in a parallel manner with 
the corresponding building blocks or amino acids. Thus, 
increase in molecular weight in only few synthetic steps is 
facilitated. 
 
Scheme 1. Lysine as branching point 
 
For the generation of four- and five-arm oligomers, different artificial amino acids 
containing the 1,2-diamioethane motif were used (Fig. 6 A). The cationic building 
block Fmoc-Stp(boc)3-OH with three protonable amino groups was first developed 
and synthesized by Dr. David Schaffert in the Wagner lab [154]. Dr. Naresh Badgujar 
(Wagner lab) similarly developed and synthesized two further building blocks which 
were used in this thesis, namely the shorter Fmoc-Gtt(boc)2-OH with two [154] and 
the new, longer building block Fmoc-Sph(boc)4-OH with four protonable amino 
groups (Fig. 6 A). All building blocks consist of an oligoamine unit with protonable 
secondary amines, a terminal primary amine and a carboxylic handle for coupling.  
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The building block unit was abbreviated with three letters as follows:  
Carboxylic handle Oligoamine unit Abbreviation
Glutaroyl- triethylentetraamine Gtt
Succinoyl- tetraethylenpentamine Stp
Succinoyl- pentaethylenhexamine Sph
 
All reactive sites were protected with adequate groups (Fig. 6 A, C) in order to avoid 
undesired side reactions. Boc is acid-labile, whereas Fmoc can be cleaved under 
basic conditions, setting free the primary amine for subsequent coupling on solid 
phase. 
The natural amino acids used in SPPS in this thesis (Fig. 6 B) bear also adequate 
side chain protection groups. Trt for thiol protection within the amino acid cysteine is, 
similar to boc, cleavable under acidic conditions (Fig. 6 B, C).  
A 
 
  
B 
 
Fig.  6. (A) Protected building blocks Gtt, Stp and Sph. The protection groups boc 
and Fmoc can be cleaved in an orthogonal manner, i.e. boc is stable under basic 
conditions and Fmoc is stable under acidic conditions. Fmoc is cleaved during 
synthesis for chain elongation; boc and Trt are cleaved simultaneously with the 
finished sequence from the solid support under acid treatment. (B) Structures of the 
used protected natural amino acids.  (C) Structures of the used protection groups. 
 
C 
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After completion of the desired sequence, the generated oligomer was cleaved off 
the solid support by acid treatment. Simultaneously, also the acid-labile protection 
groups were cleaved and the desired product was collected by filtration. 
In contrast to the convention of writing peptide sequences from N → C terminus, the 
sequences of the described oligomers in this thesis are shown from C → N terminus.  
Amino acids were abbreviated according to the one-letter code: 
Amino acid One-letter-code
Alanine A
Cysteine C
Lysine K
 
3.1.2 General synthesis and library design 
Monomers were assembled using standard amide bond formation between terminal 
amino groups and activated carboxylic groups of the next building block. Alanine-
loaded resin was modified with bis-Fmoc-lysine. Repetition of this step generated 
four amino groups which were elongated into four arms with the building blocks (BB) 
Stp, Gtt, or Sph, and in the last step with cysteine or alanine (C/A) (Scheme 2). For 
the generation of five-arm oligomers, a building block tail was introduced before 
lysine branching.  
 
 
Scheme 2. Schematic representation of four-arm generation and oligomer 
synthesis.  
An alanine preloaded resin was modified with bis-Fmoc-lysine, thus generating four 
arms. Subsequently, cationic building blocks were reacted and, depending on the 
sequence, terminal cysteines or alanines.  
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Stp
n = 2 - 5
nn
n = 1 - 5
n
nn = 2 - 4
Gtt
Sph
n = 3 - 4
n
After cleavage from the solid support, the oligomers provide a carboxylic end (C-
terminus) and four N-terminal primary amines (Fig. 7). By these means, a small 
library of various four- and five-arm oligomers was generated (Fig. 7, left panel), first 
using Stp with three protonable amines as building block. Different chain lengths and 
thus increasing molecular weight were tested for Stp oligomers, starting with one up 
to five building blocks per arm. Subsequently, terminal cysteines were introduced for 
polyplex stabilization by intramolecular disulfide formation. Furthermore, as Stp was 
not the only available building block suitable for solid-phase synthesis, for the most 
efficient oligomers Stp was replaced with two further building blocks: on the one hand 
the shorter Gtt with only two, on the other hand the longer Sph with four protonable 
amines (Fig. 7, right panel). By this variation, conclusions could be drawn on the 
impact of the length of the diaminoethane unit on cargo binding and delivery.  
 
 
 
 
 
 
Fig.  7. Library design of four- and five-arm oligomers containing different 
building blocks and terminal cysteine or alanine modification.  
 
All oligomers were purified by either by dialysis (unmodified Stp oligomers) or SEC in 
order to remove residual scavengers or small molecular weight impurities. Fig. 8 
shows exemplary analytical IEX (unmodified Stp oligomers) and RP-HPLC traces of 
selected compounds. No significant impurities could be observed. Further analytical 
IEX traces of unmodified Stp compounds are shown in Appendix 7.3.  
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A       B 
   
C       D 
  
Fig.  8.  (A) Analytical IEX trace of four-arm Stp oligomer 403 with 5 Stp/arm and   
analytical RP-HPLC traces of (B) 533, Stp5-A (C) 527, Gtt4-A (D) 535, Sph4-A.  
 
3.1.3 Four-arm Stp oligomers for pDNA delivery 
First, the cationic building block Stp was used for the generation of four-arm gene 
carriers with increasing arm length up to five Stp/arm. 
Measurements on particle size and surface charge of pDNA polyplexes (Fig. 9 A) 
show  that with increasing N/P ratio (i.e. molar ratio of protonable nitrogens to 
phosphates) the particle size decreases due to higher charge density, whereas 
oligomers with 5 Stp/arm complex pDNA to the smallest particle size. Oligomers with 
only 1 Stp/arm are not able neither to form measurable particles, nor to compact 
pDNA efficiently so as to result in positive surface charge. Starting with 2 Stp/arm, all 
particles display a positive zeta potential. 
The binding efficiency of unmodified Stp oligomers to pDNA was evaluated by 
agarose gel electrophoresis (Fig. 9 B). This assay displays the effect of increasing 
amount of building block/arm. The longer the sequence, the stronger also the binding 
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of the cargo, whereas oligomers with 1 Stp/arm did not bind pDNA at all and starting 
with three Stp/arm pDNA is fully bound at all N/P ratios.  
 
A 
 
n.d.: not detectable 
 
B 
 
 
Fig.  9. (A) Particle size and zeta potential of Stp oligomers/pDNA polyplexes at 
increasing N/P ratios. (B) pDNA binding assay of Stp oligomers at different N/P 
ratios. 
 
Four-arm Stp oligomers were tested in vitro on Neuro2A cells on their efficiency as 
gene carriers by Thomas Fröhlich (Wagner lab). Fig. 10, upper panel, shows the 
results of the luciferase reporter gene assay. Oligomers with one or two building 
blocks/arm did not have any effect, whereas starting with three Stp/arm gene delivery 
efficiency increases. Nevertheless, a maximum in efficiency is achieved with 
compound 289 containing four Stp/arm; a longer chain does not show any further 
benefit. Furthermore, even the best compounds showed only a moderate transfection 
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efficiency compared to `gold standard` linPEI. No negative effects on cell metabolic 
activity could be observed in the MTT assay, though (Fig. 10, lower panel). 
 
Fig.  10. Luciferase reporter gene assay of four-arm Stp oligomers at increasing N/P 
ratios and corresponding cell viability data below (experiment performed by Thomas 
Fröhlich, Wagner lab).  
 
Therefore, as these oligomers left room for optimization in terms of gene delivery, 
cysteines were introduced as activity enhancing amino acids.  
3.1.4 Effect of introduction of cysteines 
As cysteines are known to be able to stabilize polyplexes by cross-linking due to 
disulfide bond formation, these amino acids were introduced at the N-terminus of Stp 
oligomers with 2 -5 building blocks/arm and evaluated biophysically and biologically. 
Alanines were used as control amino acid in order to exclude possible effects due to 
arm elongation. 
The strength of the electrostatic interaction between cationic Stp oligomers and 
negatively charged pDNA was investigated by agarose gel electrophoresis (Fig. 11 
A). At first, oligomers were pre-incubated with pDNA at room temperature in air-
saturated buffer to allow (in the case of cysteine-containing oligomers) oxidative 
disulfide formation after initial complex formation as described [155]. All Stp 
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oligomers showed good pDNA binding abilities, independent of cysteine modification. 
Transfections (performed by Petra Kos, Wagner lab) demonstrated that the presence 
of terminal cysteines has a very positive impact on luciferase gene transfer (similar 
efficiency as linPEI), whereas chain length is a less important feature (Fig. 11 B, 
upper panels). Optimal efficiency is reached with cysteine modified four-arm Stp 
oligomers 392 and 402 with three and four Stp units per arm, respectively. 421 with 
five Stp per arm shows no further improvement. The alanine-ended mutants are by 
far not as effective as the cysteine oligomers. pDNA polyplexes were well tolerated 
by cells even at high N/P ratios (Fig. 11 B, lower panels). 
As the standard binding assay did not disclose differences in pDNA binding affinity, a 
polyplex dissociation assay was carried out (Fig. 11 C). Oligomers were incubated 
with pDNA under oxidative conditions and then treated with different concentrations 
of heparin to challenge electrostatic interactions between cationic carrier and 
negatively charged cargo. In parallel, polyplexes were also treated with TCEP for 
cleavage of formed disulfide bonds, and with both TCEP and heparin at a medium 
dose. Agarose gel electrophoresis (Fig. 11 C) after treatment with heparin at 
increasing concentrations showed that polyplexes formed with cysteine-modified 
oligomers are more stable than the alanine mutants. Low dose heparin dissociates all 
alanine but none of the cysteine containing structures. At medium heparin dose, 
cysteine containing polyplexes with four Stp units per arm are more stable than those 
with three Stp units. The effect of combined heparin/TCEP treatment can be seen 
best for polyplex formed with oligomer 402. It is stable under single treatment with 
each heparin or TCEP, but the cargo is released when both reagents are present. 
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C 
 
Fig.  11. (A) pDNA binding assay of cysteine- and alanine-modified four-arm Stp 
oligomers. (B) Luciferase gene transfer (Neuro2A cells) and corresponding metabolic 
cell activities below (experiment performed by Petra Kos, Wagner lab). (C) pDNA 
polyplex dissociation assay of four-arm Stp oligomers. Polyplexes were formed at 
N/P 12 and treated as follows: lane 1: polyplex, 2: polyplex + 0.1 I.U. heparin, 3: 
polyplex + 0.2 I.U. heparin, 4: polyplex + 0.4 I.U. heparin, 5: polyplex + TCEP, 6: 
polyplex + TCEP + 0.2 I.U. heparin. 
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3.1.5 Effect of Stp replacement by shorter building block Gtt 
Next, the shorter triethylene tetramine-based building block Gtt was used for 
assembly of analogs of the most efficient Stp oligomers with three and four building 
blocks/arm. Only the cysteine-modified Gtt oligomers formed oligomer/pDNA 
complexes stable in the electrophoretic binding assay (Fig. 12 A, left panel); the 
alanine mutants did not bind pDNA effectively, as shown by the laddering in Fig. 12 
A, right panel. This is the result of either not completely bound pDNA or polyplex 
instability during electrophoresis. Consistently, only Gtt3-C (492) and Gtt4-C (494) 
mediated luciferase gene transfer (Fig. 12 B), whereas the alanine-modified Gtt four-
arms displayed even lower activity than the alanine-modified Stp four-arms 
(experiment performed by Petra Kos, Wagner lab). 
 
A 
  
B 
 
Fig.  12. (A) pDNA binding assay of cysteine- and alanine modified Gtt oligomers. (B) 
Luciferase assay and corresponding cell metabolic activities (experiment performed 
by Petra Kos, Wagner lab).  
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3.1.6 Effect of Stp replacement by longer building block Sph 
The new building block Sph (with one additional amino ethane unit) was applied in 
assembly of oligomers with three and four building blocks per arm and N-terminal 
cysteines or alanines. Sph oligomers did bind their cargo very efficiently independent 
of end-modification (Fig. 13 A). A polyplex dissociation assay (Fig. 13 B) confirms 
the stabilizing effect of the cysteines.  
A 
  
B 
 
Fig.  13. (A) pDNA binding assay of cysteine-/alanine-Sph oligomers. (B) 
Dissociation assay of polyplexes (N/P 12) treated as follows: lane 1: polyplex, 2: 
polyplex + 0.1 I.U. heparin, 3: polyplex + 0.2 I.U. heparin, 4: polyplex + 0.4 I.U. 
heparin, 5: polyplex + TCEP, 6: polyplex + TCEP + 0.2 I.U. heparin. 
 
Biological evaluation of polyplexes displayed the superiority of the Sph building block 
in terms of luciferase reporter gene transfer and no notable cytotoxicity even at high 
N/P ratios (Fig. 14 A, experiment performed by Petra Kos, Wagner lab). The alanine-
ended oligomers showed equal transfection efficiency as linPEI, the cysteine 
modified compounds were even up to 60-fold more efficient than linPEI.  
The cysteine-ended four-arms Gtt4-C, Stp4-C and Sph4-C were compared in their 
pDNA compaction ability in an ethidium bromide exclusion assay (Fig. 14 B). When a 
polycation binds and compacts pDNA, the intercalator fluorescence is significantly 
reduced. LinPEI was used as a control with high compaction activity. This assay 
shows that Sph oligomers were the most potent in terms of pDNA compaction ability, 
whereas Gtt oligomers do not compact pDNA efficiently. 
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Fig.  14. (A) Luciferase gene transfer and corresponding metabolic cell activities 
(experiment performed by P. Kos). (B) Ethidium bromide exclusion assay of cysteine-
modified oligomers of different building blocks (4 units per arm). 
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Particle sizes and zeta potential of four-arm polyplexes are listed in Table 1. Zeta 
potential obtained with cysteine-modified four-arms Gtt4-C, Stp4-C and Sph4-C (all 
with 4 units per arm) were around +25 mV. Particles sizes of 496 nm, 367 nm and 
258 nm, respectively, however clearly differed and indicated a correlation of pDNA 
compaction with aminoethane numbers in the building block.  
 
 
Table 1. Particle size and zeta potential of four-arm oligomers after complexation 
with pDNA at N/P 12. 
 
3.1.7 Four-arm cysteine containing Stp, Gtt and Sph oligomers for 
siRNA delivery  
The synthesized oligomers were also tested in siRNA-mediated gene silencing. The 
binding of oligomers to siRNA evaluated by gel electrophoresis (Fig. 15 A) shows 
that cysteine-ended Stp and Sph oligomers have the strongest interaction with 
siRNA. Gtt analogs hardly bind siRNA, except oligomer 494 at high N/P. 
The ethidium bromide exclusion assay (Fig.15 B) shows that Stp and Sph oligomers 
have equal siRNA compaction ability, much more efficiently than Gtt oligomers. 
LinPEI, although it compacts siRNA, shows only weak gene silencing efficiency [160]. 
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Fig.  15. (A) siRNA binding assay of oligomers containing different building blocks. 
(B) Ethidium bromide exclusion assay.  
 
 
Gene silencing experiments (Fig. 16; experiments performed by Thomas Fröhlich 
and Petra Kos, Wagner lab) demonstrate that only cysteine-ended oligomers based 
on Stp or Sph (but not Gtt) were bioactive. Alanine-ended four-arms did not mediate 
any gene silencing effect. In contrast to pDNA delivery, Sph oligomers were not 
beneficial compared with Stp based oligomers. 
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Fig.  16. Luciferase reporter gene silencing with (A) Stp- (B) Gtt- and (C) Sph-
based oligomers (experiments performed by Thomas Fröhlich and Petra Kos, 
Wagner lab).  
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3.1.8 Five-arm Stp oligomers for pDNA and siRNA delivery 
As it is known that polymer size is important especially for pDNA delivery, longer Stp 
oligomers than plain four-branch were synthesized on solid phase by introduction of a 
Stp tail before branching and terminal cysteines. These oligomers were also 
evaluated for their properties to bind and deliver pDNA and siRNA. 
Fig. 17 A shows the results obtained for pDNA binding in the gel shift assay. It is 
obvious that all compounds can efficiently bind pDNA, as also shown in the ethidium 
bromide exclusion assay, where 425 has the same cargo compaction ability as the 
four-arm counterpart 402 
(Fig. 17 B). Nevertheless, in 
the luciferase reporter gene 
assay the five-arm 
oligomers did not show any 
superiority compared to 
four-arm oligomers (Fig. 17 
C C, experiment performed by 
Thomas Fröhlich). As the 
synthesis is more time 
consuming, improvement of 
this class of oligomers was 
not further pursued.   
 
 
Fig.  17.  (A) pDNA binding assay. (B) Ethidium bromide exclusion assay (C) 
Luciferase assay of cysteine-containing five-arm Stp oligomers and corresponding 
cell viability data (experiment performed by Thomas Fröhlich, Wagner lab).  
 
 
 
 
B
C 
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Nevertheless, the five-arm oligomers were also tested for their efficiency to bind and 
deliver siRNA. The siRNA binding assay shows that only the biggest compound 425 
can efficiently bind siRNA (Fig. 18 A). Although comparable in compaction efficiency 
to the four-arm counterpart (Fig. 18 B), efficient gene silencing could only be 
achieved with 414 (Fig. 18 C, experiment performed by Thomas Fröhlich, Wagner 
lab). 
A        
 
 
B 
 
C 
 
Fig.  18.  (A) siRNA binding assay (B) Ethidium bromide exclusion assay. (C) 
Luciferase gene silencing of cysteine-modified five-arm Stp oligomers (experiment 
performed by Thomas Fröhlich, Wagner lab).  
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3.2 Histidine-containing Stp and Gtt oligomers 
3.2.1 Introduction 
Escaping the cellular endosome before its maturation to lysosomes is a crucial and 
transfection limiting step before the nucleic acid reaches its site of action. Different 
strategies have been exploited so as to overcome this obstacle.  
One possibility is to take advantage of the proton sponge effect, as described for PEI 
[77]. Therefore, protonable amino groups at an acidic pH of 5-6 are required. 
Secondary amines within the PEI chain fulfill this demand, but also the amino acid 
histidine, for instance, with its imidazole side chain (Fig. 19). This residue serves as 
pH-selective proton sponge, as protonation does not occur before entering the acidic 
endosome.  
 
Fig.  19. Amino acid histidine 
 
 
 
 
Due to this side chain feature, namely facilitation of endosomal escape and thus 
enhanced payload delivery, various synthetic carriers [161], such as dendrimers 
[162], cationic polymers [163-165] and lipids [166, 167] have been modified with 
histidine or imidazole.  
Therefore, selected Stp and Gtt oligomers were modified with additional histidines 
and evaluated for the impact on biophysical polyplex properties and nucleic acid 
transfection. Additionally, as control compounds, four-arm lysine-histidine oligomers 
based on previous publications by the group around A. J. Mixson [146, 147] were 
synthesized and compared to Stp and Gtt containing oligomers. 
3.2.2 Library design and chemical characterization 
Based on results described in section 3.1, cysteine and alanine containing four-arm 
Stp and Gtt oligomers were further modified with histidines. First, additional histidines 
were introduced after each coupling of the corresponding building block (Fig. 20 A; 
‘lowHis’, bottom left scheme). A higher amount of histidines was synthetically 
achieved by introduction of the amino acid before coupling the second branching 
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point and also, additionally, before coupling the terminal cysteine or alanine (Fig. 20 
A; ‘highHis’, bottom right scheme). Alanine was applied as substitute control amino 
acid for cysteine and histidine, respectively. As additional control sequences, lysine-
histidine oligomers based on [146] were synthesized and evaluated (Fig. 20 B). 
 
A 
   
 
 
 
 
 
 
 
 
B 
 
 
Fig.  20.  (A) Histidine containing four-arm Stp and Gtt oligomers. Histidines were 
introduced either before building block coupling (lowHis, left scheme) or before the 
second branching point and before and after each building block (highHis, right 
scheme). Oligomers were N-terminally modified with cysteines. Alanines were used 
as control amino acids for both histidine and cysteine. (B) Control sequence based 
on [146]. 
 
Results 51 
Thus, a small library of 18 histidine-containing oligomers and corresponding mutant 
sequences was generated. All oligomer Ids and accordant sequences with detailed 
specifications on molecular formula, molecular weight and amount of protonable 
amines are listed below.  
 
Oligomer 
Id 
Sequence Molecular Formula 
Molecular 
weight 
[g/mol] 
Protonable 
amines 
487 A-K-(K-((H-Stp)3-C)2)2 C250H449N107O44S4 5786.19 52 
528 A-K-(K-((A-Stp)3-C)2)2 C214H425N83O44S4 4993.45 40 
490 A-K-(K-((H-Stp)3-A)2)2 C250H473N107O44 5682.12 52 
495 A-K-(K-((A-Stp)3-A)2)2 C214H425N83O44 4865.19 40 
521 A-K-(K-((H-Gtt)3-C)2)2 C237H411N95O45S4 5439.67 40 
524 A-K-(K-((A-Gtt)3-C)2)2 C201H387N71O45S4 4646.93 28 
522 A-K-(K-((H-Gtt)3-A)2)2 C237H411N95O45 5311.41 40 
525 A-K-(K-((A-Gtt)3-A)2)2 C201H387N71O45 4518.67 28 
573 A-K-(H-K-((H-Stp)3-H-C)2)2 C285H489N125O51S4 6611.00 58 
575 A-K-(A-K-((A-Stp)3-A-C)2)2 C231H453N89O51S4 5421.89 40 
574 A-K-(H-K-((H-Stp)3-H-A)2)2 C285H489N125O51 6482.74 58 
576 A-K-(A-K-((A-Stp)3-A-A)2)2 C231H453N89O51 5293.63 40 
577 A-K-(H-K-((H-Gtt)3-H-C)2)2 C261H429N113O51S4 6094.19 46 
579 A-K-(A-K-((A-Gtt)3-A-C)2)2 C207H393N77O51S4 4905.08 28 
578 A-K-(H-K-((H-Gtt)3-H-A)2)2 C261H429N113O51 5965.93 46 
580 A-K-(A-K-((A-Gtt)3-A-A)2)2 C207H393N77O51 4776.82 28 
582 A-K-(K-(K-H-(K-H2)3-K-H-K)2)2 C357H555N151O61 7938.20 56 
584 A-K-(K-(K-H-(K-H2)5-K-H-K)2)2 C389H597N167O67 11157.97 80 
 
Table 2. List of histidine-containing oligomers. First eight sequences (shaded 
light gray) are lowHis oligomers, subsequent eight sequences are highHis oligomers 
and sequence 582 and 584 (shaded dark grey) are control compounds based on 
[146]. 
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The purity of the terminal alanine-containing oligomer with the highest molecular 
weight out of each class (lowHis and highHis) was determined, besides 1H-NMR, by 
RP-HPLC. No significant impurities could be observed (Fig. 21). 
A      B 
  
C      D 
  
Fig.  21. Analytical RP-HPLC traces of histidine-containing oligomers. (A) (H-
Stp)3-A, 490 (B) (H-Gtt)3-A, 522 (C) (H-Stp)3-H-A, 574 (D) (H-Gtt)3-H-A, 578. 
 
3.2.3 Biophysical and biological characterization 
The effect of histidine introduction on oligomer buffering capacity was determined via 
acidimetric titrations (experiment performed by Ulrich Lächelt, Wagner lab). The 
results show the enhanced buffering effect mediated by histidines compared to 
alanine-containing compounds (Fig. 22), also increasing with the amount of histidines 
within the oligomers (Fig. 22, left panel vs. right panel). Moreover, the building block 
Gtt containing two protonable amines shows a higher buffering capacity than Stp with 
three protonable amines per unit. The results with control oligomer 584 (KHH5) are in 
the range of His-containing Stp compounds. 
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Fig.  22. Acidimetric titration of selected histidine-containing oligomers compared to 
alanine controls (experiment performed by Ulrich Lächelt, Wagner lab).  
 
LowHis oligomers were tested for their pDNA binding ability by gel electrophoresis. 
This assay revealed that all Stp oligomers apart from compound 490 (with histidines 
and terminal alanine) bind their cargo efficiently. For the Gtt oligomers, in contrast, 
histidine containing compounds distinctly exceed the alanine controls (with or without 
terminal cysteines) in their binding capacity (Fig. 23 A). 
The luciferase assay displays the difference in the impact of histidines on Stp and Gtt 
oligomers (Fig. 23 B, upper panels). Concerning Stp oligomers, histidines were 
beneficial in case of cysteine-containing compounds, whereas for the terminal 
alanine modification no improvement could be observed. For Gtt oligomers, histidines 
increased gene delivery efficiency for both terminal cysteine and alanine 
modification;for the latter the difference in transfection efficiency at higher N/P ratios 
was highly significant.  
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Fig.  23. (A) pDNA binding assay of histidine containing oligomers. Luciferase assay 
of histidine containing (B) Stp oligomers and Gtt oligomers and corresponding cell 
viability data below (experiments performed by Petra Kos, Wagner lab).  
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Furthermore, these compounds were also tested for the ability to mediate gene 
silencing with siRNA. The capability to bind siRNA was tested by agarose gel 
electrophoresis and revealed that cysteine containing Stp oligomers, consistent with 
previous findings, have the best binding abilities due to polyplex stabilization, 
whereas histidines do not have a positive influence on cargo binding (Fig. 24 A). 
However, gene silencing experiments showed that histidines definitely have an 
impact on siRNA transfection and are beneficial as an additional buffering domain, 
even leading to a gene silencing effect for Gtt oligomers, although some unspecific 
toxicity could also be observed (Fig. 24 B). 
A 
   
   
B       
 
 
Fig.  24.  (A) siRNA binding assay. (B) Gene silencing evaluation of histidine 
containing oligomers (experiments performed by Petra Kos, Wagner lab). 
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Oligomers with a higher amount of histidines (highHis) were also tested for their 
pDNA binding capacity. Fig. 25 shows that both cysteine-containing Stp and Gtt 
oligomers do efficiently bind their cargo. Binding ability declines for histidine-
containing oligomers with terminal alanine. Compound 580 ((A-Gtt)3-A-A) cannot 
retain pDNA at all.  
 
  
 
Fig.  25. pDNA binding assay of highHis oligomers. 
 
Subsequent gene delivery experiments (Fig. 26) displayed similar results as obtained 
with lowHis compounds, showing no significant improvement due to additional 
histidines.    
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Fig.  26.  Luciferase assay of highHis oligomers and corresponding cell viability data 
below (experiments performed by Petra Kos, Wagner lab).  
 
Control oligomers 582 (KHH3) and 584 (KHH5) both showed in the gel 
electrophoresis assay efficient pDNA binding (Fig. 27 A). Transfection efficiency, 
though, did not exceed linPEI level (Fig. 27 B). Therefore, four-arm Stp and Gtt 
oligomers containing histidines and terminal cysteine remain the most efficient 
compounds. 
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Fig.  27.  (A) pDNA binding assay of control lysine-histidine oligomers. (B) Luciferase 
assay and corresponding cell viability data (experiments performed by Petra Kos, 
Wagner lab). 
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3.3 Polypropylenimine (PPI) conjugates for pDNA 
delivery 
3.3.1 Introduction 
Efficient pDNA delivery with cationic oligomers is known to be dependent also on 
polymer size. The `gold standard` in terms of transfection linear PEI, for instance, has 
a molecular weight of 22 kDa and owes its effectivity also to this feature. High 
molecular weight, though, is also strongly associated with carrier toxicity [49, 103]. 
Due to its static structure, accumulation occurs in cells or organs of living systems, 
causing undesired toxic effects. Low Mw gene vectors, on the other hand, may not 
provide sufficient polyplex stability in vivo during blood circulation [114, 168, 169]. 
Therefore, connection of non-toxic small Mw compounds by biodegradable linkages 
into larger polymeric structures is a possible solution [106, 114, 168, 170-174] for this 
problem.  
In 2008, our lab (Russ and colleagues) presented a method for assembly of better 
defined structures to so-called `pseudodendrimers` by connecting oligoethylenimine 
(OEI) units with the biodegradable linker hexanedioldiacrylate (HD) (Fig 28 A), 
resulting in efficient, high Mw, biocompatible gene carriers [119]. In a subsequent 
work, the structurally defined dendrimer polypropylenimine (PPI) was used as a core 
structure and was connected with the same HD linker to either PPI or 
oligoethylenimine units [135]. Nevertheless, uncertainty of the resulting structure still 
remained due to its polydisperse nature and absence of precise connection sites.  
In 2007 Kim et al. could show that simple PPI surface modification with arginine as 
additional cationic domain can enhance pDNA transfection efficiency [134]. 
In order to allow more precise conclusions on structure-activity relationships, this part 
of the thesis focuses on the generation of more defined biodegradable gene vectors 
with higher molecular weight and biocompatibility. Therefore, the dendrimer 
polypropylenimine (PPI) G2 was used again as a core, as it has a defined structure 
and does not display noteworthy toxicity. Furthermore, its moderate efficiency 
concerning pDNA transfection leaves room for improvement. Small linear, sequence-
defined oligomers consisting of increasing numbers of the building block Stp were 
used for further modification, as previous experiments in our lab showed that these 
small oligomers are neither efficient for gene delivery, nor toxic. The aim was to find 
out whether a combination of these compounds would bring any benefit. Disulfide 
bonds were chosen as a biodegradable linkage between these compounds, as these 
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could be generated in a controlled manner and are rather stable in the extracellular 
environment, not leading to polymer degradation until reaching the reducing cytosolic 
environment (Fig. 28 B).  
A       B 
   
Fig.  28. (A) Pseudodendrimers consisting of HD-linked OEI units (see Russ et al 
[135]). (B) Defined dendritic structures consisting of PPI G2 core linked via disulfide 
linkages to sequence-defined Stp oligomers. 
 
3.3.2 Synthetic concept 
In order to facilitate reaction of PPI with cysteine-containing linear Stp oligomers, the 
eight primary amines on the PPI dendrimer surface had to be activated. 3-Nitro-2-
pyridinesulfenyl (NPys) modified cysteine (BCNP, Fig. 29 compound 1) was chosen 
for this purpose, as the NPys acts as both protecting and activating group for the 
cysteine thiol, thus allowing concerted disulfide bond formation.  
Therefore, the BCNP carboxylic group was activated with pentafluorophenol (Fig. 29, 
compound 2), in order to facilitate reaction with the PPI primary amines. After PPI 
modification to PPI-BCNP (Fig. 29, compound 4), the excess BCNP was removed 
and the acid-labile boc protecting group was cleaved, leading to PPI-CNP (Fig. 29, 
compound 5). Subsequently, PPI-CNP was reacted with cysteine containing linear 
oligomers with 1 - 4 and 5 Stp units. The generated nitropyridine-thione was removed 
by dialysis (Fig. 29, last reaction step), resulting in compound 6. 
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Fig.  29. Synthetic concept of PPI conjugates.  
First, Boc-Cys(NPys)-OH was activated with pentafluorophenol to BCNP-OPfp 3 and 
subsequently reacted with PPI G2 to PPI-BCNP 4. After precipitation for excess 
BCNP-OPfp removal, PPI-BCNP 4 was deprotected, resulting in PPI-CNP 5. PPI-
CNP was subsequently reacted with linear, cysteine-containing Stp oligomers and 
purified by dialysis to yield compound 6 (n = 1-3, 5).  
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3.3.3 Chemical characterization 
Identity of synthesized intermediates 4 and 5 was confirmed by 1H-NMR. Fig. 30 
shows the spectra of PPI after reaction with BCNP (A) and after cleavage of the boc 
protection group (B). Integration confirmed full modification of the PPI core with 
BCNP.  
 
A      B 
 
Fig.  30. 1H-NMR spectra of (A) PPI-BCNP 4 in MeOH-D4 and (B) PPI-CNP 5 in D2O.  
 
In order to allow concerted and precise modification of the activated PPI, purity of the 
PPI-CNP core compound had to be ensured. This was confirmed by analytical RP-
HPLC (Fig. 31). The analytical run was monitored at two wavelengths: 220 nm (Fig. 
31, red chromatogram) for amide bond and 340 nm (black chromatogram) for NPys 
detection. The overlay shows that NPys can only be found in the highly pure product 
peak. 
 
Fig.  31. Analytical RP-HPLC trace of purified PPI-CNP 5 performed on a C18 column 
and monitored at 220 nm (red chromatogram) and 340 nm (black chromatogram).   
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Linear Stp oligomers with increasing chain length (n= 1-3, 5) were generated by 
SPPS and product identity was confirmed by 1H-NMR. Subsequently, reaction 
progress of PPI-CNP with linear Stp oligomers was monitored in situ by 
spectrophotometric quantification of the released nitropyridine-thione. After dialysis 
and lyophilization of the products 6 with n=1-3, 5 (see Figure 33 A), completion of 
reaction could be confirmed by lack of NPys protons in the 1H-NMR spectrum (Fig. 
32). Successful synthesis of the desired compound was further confirmed by 
additional quantification of generated disulfide bonds by the TCEP assay and lack of 
free thiols (Ellman`s assay). 
 
 
Fig.  32. Exemplary 1H-NMR spectrum of compound 6, n=2, obtained by reaction of 
PPI-CNP 5 with C-Stp2.   
 
3.3.4 Biophysical and biological characterization 
Dynamic light scattering measurements show that all PPI-(C-C-Stpn)8/pDNA 
polyplexes are approximately 200 – 400 nm in size. Attempted particle formation of 
pDNA with PPI G2 displayed only aggregates with a size of > 1 µm. Surface charge 
of all polyplexes was above +20 mV (Fig. 33 A). 
The binding efficiency of the PPI conjugates to pDNA was determined by gel 
electrophoresis. Only PPI G2 and compound 536 with 5 Stp/chain were able to fully 
bind pDNA at all N/P. Concerning the smaller conjugates, the longer the Stp chain, 
the higher also the binding affinity (Fig. 33 B).   
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Fig.  33.  (A) Particle size and zeta potential of PPI conjugate/pDNA polyplexes 
formed at N/P 12. (B) pDNA binding assay.  
 
PPI conjugates were evaluated for their gene delivery efficiency and cytotoxicity on 
Neuro2A cells. Consistent with the biophysical characterization results, in the 
luciferase assay compound 418 with 1 Stp/chain showed the lowest efficiency 
compared to PPI G2 alone and control linPEI. Best results in terms of transfection 
efficiency could be achieved with conjugates containing 3 and 5 Stp/chain, whereas 
the longest chain did not bring any significant benefit. All compounds did not affect 
the cell metabolic activity, thus displaying high biocompatibility (Fig. 34, experiments 
performed by Petra Kos).     
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Fig.  34. Luciferase assay of transfections with PPI-C-(C-Stpn)8 polymer 6/pDNA 
complexes and corresponding cell viability data (experiments performed by Petra 
Kos).  
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4 DISCUSSION 
Nucleic acid delivery with cationic polymers is often hindered by low efficiency and 
toxicity. Among others, cationic polymers like polyethylenimine have the ability to 
reversibly compact pDNA through electrostatic interaction into stable polyplexes. 
Thus, the payload can reach undamaged the target cell compartment, namely the 
nucleus, where it can fulfil its task.   
Such polymers, although showing promising results in terms of transfection efficiency 
and cytotoxicity, are still accompanied by a crucial drawback which hampers 
essential structure-activity relationship studies: polydispersity. 
The concept of solid-phase supported synthesis (SPS) shows a way out of this 
dilemma. This method allows step-by-step polymer chain elongation and therefore 
exact position control of the inserted compound. Beyond linear compounds, 
introduction of lysines with two primary amines each facilitates the synthesis of 
branched oligomers and easy increase of molecular weight by parallel arm elongation 
Thus, generation of precise, sequence-defined oligomers is possible, allowing 
conclusions on structure-activity relationships.  
4.1 Four- and five-arm oligo(ethanamino)amides for 
pDNA and siRNA delivery 
As already mentioned, solid-phase supported synthesis can facilitate fast assembly 
of sequence-defined cationic oligomers [153, 175-177] with exact control on the 
position of introduced modifications. Using artificial amino acids which contain the 
1,2-diaminoethane motif [154], this strategy was applied for assembling carriers for 
pDNA and siRNA [155, 159]. In the first chapter of this thesis, a small library of 
branched, four-arm oligomers was described. Two simple, straightforward 
modifications converted moderately active pDNA transfection carriers, four-arm Stp3 
(288) or Stp4 (289) [155] into 1000-fold more potent pDNA transfection agents, Sph3-
C (497) and Sph4-C (519). 
The first successful modification was the incorporation of cysteines at the N-terminal 
end of the four arms. Disulfide bonds, either directly incorporated into transfection 
carriers or, as in the current study, formed after nucleic acid complexation, can be 
very beneficial [174, 178-180], both for complex stability in the extracellular space, 
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and for biocompatibility due to cleavage of the carrier into low-molecular fragments in 
the reducing intracellular environment [109]. Consistently, the cysteine-ended 
oligomers displayed pDNA and siRNA transfection activity without significant 
cytotoxicity. Polyplex dissociation assays of Stp and Sph polyplexes confirmed the 
importance of cysteine stabilization, whereas stronger binding of the oligomers 
containing 4 building blocks/arm did not improve transfection significantly. This result 
shows that a higher binding and compaction ability is not necessarily beneficial, as it 
may hamper cargo release in the cytosol. 
In order to further increase molecular weight, a Stp tail was added before introduction 
of the lysine branching points in four-arm oligomers, thus creating cysteine-
terminated five-arm Stp compounds. Stp tails and arms correlated in length, thus 
containing 2, 3 and four Stp units. Biophysical and biological evaluation of these 
compounds, though, did not reveal any benefit compared to their four-arm 
counterparts. This finding further emphasizes the importance of the optimal structure 
for maximal activity.   
The second optimization resulted from defined variation of the artificial oligoamino 
acid building block, differing in the repeats of 1,2-diaminoethane units. This motif [78, 
83] is responsible for the high transfection activity of PEI [13, 76, 77, 174, 181] and 
related polymers [81, 82, 155, 180, 182], due to unique dynamic properties, 
reversibly changing the cationic character by endosomal protonation and mediating 
endosomal escape. Within the polyamide chains of the four-arm oligomers, each 
building block Gtt, Stp and Sph provides two terminal amide nitrogens and two, three, 
or four protonable secondary amine nitrogens per unit. For both pDNA compaction 
and transfection activity, the building blocks ranked in the very clear order of 
Sph>Stp>>Gtt. Interestingly, extending the chain lengths beyond 3 building blocks 
per arm had marginal impact on the performance. Stp5-C (421, with 64 protonatable 
nitrogens) has a far lower efficiency than Sph3-C (497, 52 protonatable nitrogens) 
and Sph4-C (519, 68 protonatable nitrogens). For the much smaller siRNA cargo, 
Sph and Stp however displayed very similar binding activity, with Stp providing best 
gene silencing efficiency. Cysteine mediated stabilization by disulfide formation was 
strictly required for siRNA delivery. In conclusion, compaction ability (especially in 
case of pDNA) and polyplex stabilization (especially for siRNA) are major delivery 
requirements. Defined carriers generated by solid-phase supported synthesis can 
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accomplish this effectively, also providing insight into structure-activity relationships 
and manifold possibilities for further improvement. 
4.2 Histidine-containing Stp and Gtt oligomers 
The amino acid histidine has due to its imidazole side chain the property for selective 
protonation at acidic pH. This feature is crucial for one of the main bottlenecks within 
nucleic acid delivery with cationic carriers – endosomal escape. Therefore, this 
additional proton sponge was already used for enhancing the transfection efficiency 
of various gene carriers [161].   
As SPS allows selective introduction of activity-enhancing moieties, histidines were 
inserted in an alternating manner into four-arm oligomers with three Stp or Gtt/arm 
and terminal cysteine. Thus, compounds with a low amount (`lowHis`) and with a 
higher amount (`highHis`) of histidines were generated. By replacing histidine and/or 
the terminal cysteine with alanine as a control amino acid, direct conclusions on 
structure-activity relationships could be drawn.  
By these means, a library of sixteen histidine-containing oligomers and alanine 
counterparts was generated. Identity and purity was confirmed by 1H-NMR and RP-
HPLC. Acidimetric titrations (experiment performed by Ulrich Lächelt, Wagner lab) 
confirmed the higher buffering capacity at acidic pH mediated by histidines compared 
to alanine-containing mutants. Also, Gtt oligomers with two protonable amines per 
unit showed a higher buffering capacity than Stp oligomers with three protonable 
amines per unit.  
In the gel electrophoresis assay, the `histidine effect` had the highest impact on Gtt 
oligomers. LowHis and highHis Gtt oligomers with terminal cysteines (521, 577) 
equalized the Stp counterparts (487, 573) in terms of pDNA binding.  Consistently, in 
the luciferase assay all these compounds showed similar transfection efficiency, 
exceeding linPEI levels and showing no cytotoxic effects. Moreover, cysteine-
terminated oligomers were, consistent with previous findings, more efficient than the 
alanine mutants due to polyplex stabilization, whereas replacement of histidine with 
alanine had a greater impact for the Gtt oligomers, leading to clearly lower 
transfection rates.   
Nevertheless, significant improvement in terms of transfection efficiency due to 
introduction of additional histidines (lowHis vs. highHis oligomers) could not be 
observed.  
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The impact of histidine-introduction could also be observed in gene silencing 
experiments. SiRNA transfection with cysteine-containing lowHis oligomers revealed 
that introduction of histidines considerably improved gene silencing compared to 
alanine mutants. Even for Gtt oligomers a silencing effect could be shown, even 
though unspecific toxicity could also be observed.    
Also, the new histidine-containing Stp and Gtt oligomers were compared with 
histidine-rich structures (582, 584) based on the work of A. J. Mixson [146]. These 
control oligomers showed transfection efficiency similar to linPEI but could not reach 
luciferase expression levels mediated by the best Stp and Gtt compounds.  
4.3 Polypropylenimine (PPI) conjugates for pDNA 
delivery 
The `gold standard` in terms of gene delivery, namely PEI, owes its efficiency also to 
its high molecular weight of 22 kDa but is polydispers by nature [76]. As high 
molecular weight of cationic polymers, though, is associated on the one hand with 
better transfection efficiency but on the other hand also with cytotoxicity [49], gene 
carriers with the feature of environment-triggered cargo release have the potential to 
overcome this drawback. Therefore, in order to increase molecular weight while 
maintaining a defined structure, the synthetic concept implied coupling the 
symmetrical polypropylenimine dendrimer [126] to linear, sequence-defined Stp 
oligomers. Biodegradability was achieved by modification of the eight primary amines 
on the PPI surface with activated cysteines, making them feasible for reaction with 
free thiols. Linear oligomers consisting of increasing amount of the cationic building 
block Stp (1-3 and 5 units) and containing a terminal cysteine with a free thiol were 
coupled to this activated core, so as to create reducible disulfide linkages. Thus, four 
compounds with increasing molecular weight were assembled (418 Stp1, 427 Stp2, 
428 Stp3, 536 Stp5) and compared to unmodified generation 2 (G2) PPI. The 
successful reaction was confirmed by chemical characterization methods.  
Biophysical evalutation of these compounds by the pDNA binding assay revealed 
that the binding affinity increases with oligomer chain length, whereas only the 
compound with the highest Mw (536 Stp5) could efficiently bind pDNA. PPI alone is 
also very efficient in terms of pDNA binding.  
Biological testing for pDNA transfection efficiency by the luciferase assay showed 
that the oligomers containing the shortest Stp chain were even less effective than PPI 
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alone; results consistent with the findings in the gel shift assay. PPI coupled to 
oligomers with 3 and 5 Stp/chain (428, 536) were the most efficient for pDNA 
delivery, whereas 536 (Stp5) did not show any significant improvement compared to 
428 (Stp3), which correlates also with the results obtained with four-arm oligomers.  
Size and zeta potential measurements also offered an explanation for the 
transfection efficiency of PPI alone – very large particle size (> 1µm) and aggregates 
facilitate cellular uptake.  
Nevertheless, transfection efficiency of the best conjugates is in the range of PEI, 
thus encouraging further efforts for optimization. Furthermore, the synthetic concept 
of PPI primary amine activation offers a platform for novel conjugates.  
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5 CONCLUSION AND OUTLOOK 
Solid-phase supported synthesis (SPS) and subsequent biological evaluation of 
branched, sequence-defined oligomers displayed their potential as efficient nucleic 
acid carriers. Optimized synthesis of plain four-arm oligomers consisting of the 
cationic building block Stp has paved the way for further carrier optimization. 
Significant enhancement of pDNA and, even more, of siRNA transfection efficiency 
was achieved by simple N-terminal cysteine introduction due to resulting enhanced 
polyplex stabilization. Additionally, the protonable amine density within the used 
building block (Gtt, Stp, Sph) has proven to also a very important feature, with Sph 
showing the highest efficiency; a finding which can be exploited for further structure 
variations. Finally, SPS facilitated introduction of histidines within four-arm oligomers, 
increasing pH-specific oligomer buffering capacity and thus transfection efficiency.  
Thus, the four-arm oligomers described in this work may be the first steps towards 
highly efficient and biocompatible nucleic acid carriers. Due to the synthetic method 
used, namely solid phase supported synthesis, there are still manifold possibilities for 
improvement and optimization. 
Furthermore, the synthetic pathway established for generation of PPI conjugates 
offers a platform for further development, as the activated dendritic core can be 
modified with further adequate moieties. Moreover, this method can be used for 
modification of other core structures with primary amines on the surface.  
In conclusion, branched cationic oligomers generated by means of SPS offer a broad 
platform as efficient and biocompatible nucleic acid carriers. Due to controlled 
sequence assembly, conclusions on structure-activity relationships are possible – a 
crucial starting point for further development of even more effective non-viral vectors. 
Furthermore, the possibility of fast combinatorial synthesis offered by SPS and 
feasible purification and analytical methods offer manifold possibilities for the 
development of novel and potent structures.  
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6 SUMMARY 
Synthetic nucleic acid carrier systems got more and more into focus during the last 
decades as they offer the opportunity to overcome drawbacks associated with viral 
vectors. Over the years, linear polyethylenimine (linPEI) has established itself as the 
`gold standard` in terms of nucleic acid transfection efficiency. Various modifications 
have even increased its effectivity and reduced toxicity, but polydispersity hampered 
precise conclusions on structure-activity relationships.  
Solid-phase supported synthesis shows a way out of this dilemma, as it offers the 
possibility for sequence-controlled assembly of cationic oligomers and also the option 
for directed sequential modifications.    
The aim of this thesis was the synthesis and optimization of branched, sequence-
defined and biocompatible oligomers via SPS for generation of highly efficient nucleic 
acid carriers. First, four-branched oligomers consisting of lysines as branching points 
and the artificial amino acid Stp were synthesized with an increasing number of Stp 
per arm. Chemical characterization confirmed identity and purity of the compounds; 
biophysical and biological evaluation showed promising results in terms of pDNA 
transfection.  
Therefore, the most potent structures were further modified with terminal cysteines 
for polyplex stabilization, which led to significant improvement in terms of pDNA 
transfection and also of gene silencing with siRNA. These results were undermined 
by gel electrophoresis assays in so far, that cysteines play a crucial role concerning 
polyplex stabilization. Additionally, further artificial oligoamino acids besides Stp with 
three protonable amines per unit were evaluated, namely Gtt with two and Sph with 
four protonable amines, respectively. The differing repeats of the 1,2-diaminoethane 
units also resulted in differing impact on pDNA delivery, ranking in the order 
Sph>Stp>>Gtt. In terms of siRNA-mediated gene silencing, Sph and Stp showed 
similar results, whereas Gtt-containing oligomers did not show any effect. Hence, it 
could be concluded that optimal oligomer/siRNA polyplex stabilization due to 
electrostatic interactions and disulfide formation is required for efficient gene 
silencing.  
Another successful modification of Stp and Gtt oligomers was the introduction of the 
amino acid histidine. Selective protonation of its imidazole side chain at acidic pH 
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enhances endosomal escape, a crucial bottleneck in the nucleic acid delivery 
pathway. Histidine-containing oligomers were more efficient concerning pDNA and 
siRNA delivery than the alanine-containing control structures, undermining the 
importance of endosomal escape for successful transfection.   
A further aim of this thesis was to generate defined, non-toxic structures with a higher 
Mw consisting of low Mw subunits coupled with biodegradable linkages. The 
structurally defined dendrimer polypropylenimine (PPI) was chosen as a core and its 
primary amines on the surface were modified in so far as to react with free thiols to 
reducible disulfide bonds. By these means, sequence-defined, linear Stp oligomers 
with increasing Stp units per chain were coupled to the activated PPI core and 
evaluated for pDNA delivery. The resulting non-toxic compounds showed correlation 
between increasing Stp chain length and transfection efficiency. 
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7 APPENDIX 
7.1 List of used compounds 
7.1.1 Four- and five-arm oligomers 
Oligomer 
Id Sequence Molecular Formula 
Molecular 
weight 
[g/mol] 
Protonable 
amines 
286 A-K-(K-(Stp)2)2 C69H143N27O13 1559.05 16 
287 A-K-(K-(Stp2)2)2 C117H243N47O21 2644.48 28 
288 A-K-(K-(Stp3)2)2 C165H343N67O29 3729.92 40 
289 A-K-(K-(Stp4)2)2 C213H443N87O37 4815.36 52 
403 A-K-(K-(Stp5)2)2 C261H543N107O45 5900.79 64 
401 A-K-(K-(Stp2-C)2)2 C129H263N51O25S4 3057.05 28 
392 A-K-(K-(Stp3-C)2)2 C177H363N71O33S4 4142.49 40 
402 A-K-(K-(Stp4-C)2)2 C225H463N91O41S4 5227.93 52 
421 A-K-(K-(Stp5-C)2)2 C273H563N111O49S4 6313.37 64 
530 A-K-(K-(Stp2-A)2)2 C129H263N51O25 2928.80 28 
531 A-K-(K-(Stp3-A)2)2 C177H363N71O33 4014.23 40 
532 A-K-(K-(Stp4-A)2)2 C225H463N91O41 5099.67 52 
533 A-K-(K-(Stp5-A)2)2 C273H563N111O49 6185.11 64 
414 A-Stp2-K-(K-(Stp2-C)2)2 C153H313N61O29S4 3599.77 34 
424 A-Stp3-K-(K-(Stp3-C)2)2 C213H447N86O38S4 4949.64 49 
425 A-Stp4-K-(K-(Stp4-C)2)2 C273H563N111O49S4 6313.37 64 
492 A-K-(K-(Gtt3-C)2)2 C165H327N59O33S4 3794.00 28 
494 A-K-(K-(Gtt4-C)2)2 C209H415N75O41S4 4763.27 36 
526 A-K-(K-(Gtt3-A)2)2 C165H327N59O33 3665.74 28 
527 A-K-(K-(Gtt4-A)2)2 C209H415N75O41 4635.01 36 
497 A-K-(K-(Sph3-C)2)2 C201H423N83O33S4 4659.31 52 
519 A-K-(K-(Sph4-C)2)2 C249H523N103O41S4 5744.74 68 
534 A-K-(K-(Sph3-A)2)2 C201H423N83O33 4531.05 52 
535 A-K-(K-(Sph4-A)2)2 C249H523N103O41 5616.48 68 
487 A-K-(K-((H-Stp)3-C)2)2 C250H449N107O44S4 5786.19 52 
528 A-K-(K-((A-Stp)3-C)2)2 C214H425N83O44S4 4993.45 40 
490 A-K-(K-((H-Stp)3-A)2)2 C250H473N107O44 5682.12 52 
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495 A-K-(K-((A-Stp)3-A)2)2 C214H425N83O44 4865.19 40 
521 A-K-(K-((H-Gtt)3-C)2)2 C237H411N95O45S4 5439.67 40 
524 A-K-(K-((A-Gtt)3-C)2)2 C201H387N71O45S4 4646.93 28 
522 A-K-(K-((H-Gtt)3-A)2)2 C237H411N95O45 5311.41 40 
525 A-K-(K-((A-Gtt)3-A)2)2 C201H387N71O45 4518.67 28 
573 A-K-(H-K-((H-Stp)3-H-C)2)2 C285H489N125O51S4 6611.00 58 
575 A-K-(A-K-((A-Stp)3-A-C)2)2 C231H453N89O51S4 5421.89 40 
574 A-K-(H-K-((H-Stp)3-H-A)2)2 C285H489N125O51 6482.74 58 
576 A-K-(A-K-((A-Stp)3-A-A)2)2 C231H453N89O51 5293.63 40 
577 A-K-(H-K-((H-Gtt)3-H-C)2)2 C261H429N113O51S4 6094.19 46 
579 A-K-(A-K-((A-Gtt)3-A-C)2)2 C207H393N77O51S4 4905.08 28 
578 A-K-(H-K-((H-Gtt)3-H-A)2)2 C261H429N113O51 5965.93 46 
580 A-K-(A-K-((A-Gtt)3-A-A)2)2 C207H393N77O51 4776.82 28 
582 A-K-(K-(K-H-(K-H2)3-K-H-K)2)2 C357H555N151O61 7938.20 56 
584 A-K-(K-(K-H-(K-H2)5-K-H-K)2)2 C389H597N167O67 11157.97 80 
 
7.1.2 Linear cysteine-containing Stp oligomers 
Sequence Molecular Formula Molecular weight [g/mol] 
Protonable 
amines 
C-Stp C15H32N6O4S 392.52 4 
C-Stp2 C27H53N11O6S 659.84 7 
C-Stp3 C39H78N16O8S 931.20 10 
C-Stp4 C51H102N21O10S 1202.56 13 
C-Stp5 C63H128N26O12S 1473.92 16 
 
7.1.3 PPI conjugates 
Conjugate 
Id 
Sequence Molecular Formula Molecular weight [g/mol] 
Protonable 
amines 
418 PPI-(C-C-Stp)8 C268H556N78O24S16 4718.51 46 
427 PPI-(C-C-Stp2)8 C280H576N110O56S16 6893.31 70 
428 PPI-(C-C-Stp3)8 C376H776N150O72S16 9064.19 94 
430 PPI-(C-C-Stp4)8 C472H976N190O88S16 11227.33 118 
536 PPI-(C-C-Stp5)8 C568H1176N230O104S16 13405.93 150 
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7.2 Analytical Data 
1H-NMR chemical shifts of the synthesized compounds (all measured at 400 MHz in 
D2O). Compound mass was not determined unless otherwise stated.  
7.2.1 Four- and five-arm oligomers 
Oligomer Id: 286       Sequence: A-K-(K-(Stp)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 16 H, -CO-CH2-
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 16 H, -CH2- Tp), 3.48-3.54 (m, 48 H, -
CH2- Tp), 4.1-4.3 (m, 4 H, αH amino acids).  
 
Calculated Mass: 1560.05 [M+H]+ 
Mass found: 1558.823 [M+H]+ 
 
Oligomer Id: 287       Sequence: A-K-(K-(Stp2)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 32 H, -CO-CH2-
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 32 H, -CH2- Tp), 3.48-3.54 (m, 96 H, -
CH2- Tp), 4.1-4.3 (m, 4 H, αH amino acids). 
 
Calculated Mass: 2645.48 [M+H]+ 
Mass found: 2646.258 [M+H]+ 
 
Oligomer Id: 288       Sequence:  A-K-(K-(Stp3)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2-
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH2- Tp), 3.48-3.54 (m, 144 H, -
CH2- Tp), 4.1-4.3 (m, 4 H, αH amino acids). 
 
Calculated Mass: 3730.92 [M+H]+ 
Mass found: 3729.070 [M+H]+ 
 
Oligomer Id: 289       Sequence: A-K-(K-(Stp4)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 64 H, -CO-CH2-
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 64 H, -CH2- Tp), 3.48-3.54 (m, 192 H, -
CH2- Tp), 4.1-4.3 (m, 4 H, αH amino acids). 
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Calculated Mass: 4186.36 [M+H]+ 
Mass found: 4187.455 [M+H]+ 
 
Oligomer Id: 403       Sequence: A-K-(K-(Stp5)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 80 H, -CO-CH2-
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 80 H, -CH2- Tp), 3.48-3.54 (m, 240 H, -
CH2- Tp), 4.1-4.3 (m, 4 H, αH amino acids). 
 
Oligomer Id: 401       Sequence: A-K-(K-(Stp2-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 32 H, -CO-CH2-
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 32 H, -CH2- 
Tp), 3.48-3.54 (m, 96 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 392       Sequence: A-K-(K-(Stp3-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2-
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH2- 
Tp), 3.48-3.54 (m, 144 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 402       Sequence: A-K-(K-(Stp4-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 64 H, -CO-CH2-
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 64 H, -CH2- 
Tp), 3.48-3.54 (m, 192 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 421       Sequence: A-K-(K-(Stp5-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 80 H, -CO-CH2-
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 80 H, -CH2- 
Tp), 3.48-3.54 (m, 240 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 530       Sequence: A-K-(K-(Stp2-A)2)2 
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 32 H, -CO-CH2-
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 32 H, -CH2- Tp), 3.48-3.54 (m, 96 H, -
CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
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Oligomer Id: 531       Sequence: A-K-(K-(Stp3-A)2)2 
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2-
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH2- Tp), 3.48-3.54 (m, 144 H, -
CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 532       Sequence: A-K-(K-(Stp4-A)2)2 
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 64 H, -CO-CH2-
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 64 H, -CH2- Tp), 3.48-3.54 (m, 192 H, -
CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 533       Sequence: A-K-(K-(Stp5-A)2)2 
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 80 H, -CO-CH2-
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 80 H, -CH2- Tp), 3.48-3.54 (m, 240 H, -
CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 414      Sequence: A-Stp2-K-(K-(Stp2-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 40 H, -CO-CH2-
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 40 H, -CH2- 
Tp), 3.48-3.54 (m, 120 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 424      Sequence: A-Stp3-K-(K-(Stp3-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 60 H, -CO-CH2-
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 60 H, -CH2- 
Tp), 3.48-3.54 (m, 180 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 425      Sequence: A-Stp4-K-(K-(Stp4-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 80 H, -CO-CH2-
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 80 H, -CH2- 
Tp), 3.48-3.54 (m, 240 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 492       Sequence: A-K-(K-(Gtt3-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 
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3.1 (t, 6 H, βH lysine), 3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -CH2- Tt), 4.1-4.3 
(m, 8 H, αH amino acids). 
 
Oligomer Id: 494       Sequence: A-K-(K-(Gtt4-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 64 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 32 H, -CO-CH2-CH2-CH2-CH2-CO-), 3.0 (m, 8 H, βH 
cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.3 (m, 64 H, -CH2- Tt), 3.4-3.5 (m, 128 H, -CH2- 
Tt), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 526       Sequence: A-K-(K-(Gtt3-A)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.1 (t, 6 H, βH lysine), 
3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -CH2- Tt), 4.1-4.3 (m, 8 H, αH amino 
acids). 
 
Oligomer Id: 527       Sequence: A-K-(K-(Gtt4-A)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 64 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 32 H, -CO-CH2-CH2-CH2-CO-), 3.1 (t, 6 H, βH lysine), 
3.2-3.3 (m, 64 H, -CH2- Tt), 3.4-3.5 (m, 128 H, -CH2- Tt), 4.1-4.3 (m, 8 H, αH amino 
acids). 
 
Oligomer Id: 497       Sequence: A-K-(K-(Sph3-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2- 
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, - CH2- 
Tp), 3.4-3.6 (m, 192 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 519       Sequence: A-K-(K-(Sph4-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 64 H, -CO-CH2- 
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 64 H, - CH2- 
Tp), 3.4-3.6 (m, 256 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
 
 
 
Appendix 79 
Oligomer Id: 534       Sequence: A-K-(K-(Sph3-A)2)2 
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2- 
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH2- Tp), 3.4-3.6 (m, 192 H, - 
CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 535       Sequence: A-K-(K-(Sph4-A)2)2 
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 64 H, -CO-CH2- 
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 64 H, -CH2- Tp), 3.4-3.6 (m, 256 H, - 
CH2- Tp), 4.1-4.3 (m, 8 H, αH amino acids). 
 
Oligomer Id: 487           Sequence: A-K-(K-((H-Stp)3-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2- 
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1-3.2 (m, 32 H, βH lysine, histidine), 3.2-3.4 
(m, 48 H, -CH2- Tp), 3.48-3.54 (m, 144 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH lysine, 
alanine, cysteine), 4.7 (m, 12 H, αH histidine) 7.3 (12 H, imidazole H histidine), 8.6 
(12 H, imidazole H histidine). 
 
Oligomer Id: 528      Sequence: A-K-(K-((A-Stp)3-C)2)2 
δ (ppm) = 1.3-1.8 (m, 57 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2- 
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH2- 
Tp), 3.48-3.54 (m, 144 H, -CH2- Tp), 4.1-4.3 (m, 20 H, αH amino acids). 
 
Oligomer Id: 490      Sequence: A-K-(K-((H-Stp)3-A)2)2 
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2- 
CH2-CO-), 3.1-3.2 (m, 32 H, βH lysine, histidine), 3.2-3.4 (m, 48 H, -CH2- Tp), 3.48-
3.54 (m, 144 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH lysine, alanine), 4.7 (m, 12 H, αH 
histidine) 7.3 (12 H, imidazole H histidine), 8.6 (12 H, imidazole H histidine). 
 
Oligomer Id: 495      Sequence: A-K-(K-((A-Stp)3-A)2)2 
δ (ppm) = 1.3-1.8 (m, 69 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2- 
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH2- Tp), 3.48-3.54 (m, 144 H, -
CH2- Tp), 4.1-4.3 (m, 20 H, αH amino acids). 
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Oligomer Id: 521      Sequence: A-K-(K-((H-Gtt)3-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2- 
CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 
3.1-3.2 (m, 32 H, βH lysine, histidine), 3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -
CH2- Tt),, 4.1-4.3 (m, 8 H, αH lysine, alanine, cysteine), 4.7 (m, 12 H, αH histidine) 
7.3 (12 H, imidazole H histidine), 8.6 (12 H, imidazole H histidine). 
 
Oligomer Id: 524      Sequence: A-K-(K-((A-Gtt)3-C)2)2 
δ (ppm) = 1.3-1.8 (m, 57 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 
3.1-3.2 (m, 6 H, βH lysine), 3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -CH2- Tt),, 
4.1-4.3 (m, 20 H, αH amino acids). 
 
Oligomer Id: 522      Sequence: A-K-(K-((H-Gtt)3-A)2)2 
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.1-3.2 (m, 32 H, βH 
lysine, histidine), 3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -CH2- Tt), 4.1-4.3 (m, 
8 H, αH lysine, alanine), 4.7 (m, 12 H, αH histidine) 7.3 (12 H, imidazole H histidine), 
8.6 (12 H, imidazole H histidine). 
 
Oligomer Id: 525      Sequence: A-K-(K-((A-Gtt)3-A)2)2 
δ (ppm) = 1.3-1.8 (m, 69 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.1-3.2 (m, 6 H, βH 
lysine), 3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -CH2- Tt), 4.1-4.3 (m, 20 H, αH 
amino acids). 
 
Oligomer Id: 573      Sequence: A-K-(H-K-((H-Stp)3-H-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2-
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1-3.2 (m, 36 H, βH lysine, histidine), 3.2-3.4 
(m, 48 H, -CH2- Tp), 3.48-3.54 (m, 144 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH lysine, 
alanine, cysteine), 4.7 (m, 14 H, αH histidine) 7.3 (14 H, imidazole H histidine), 8.6 
(14 H, imidazole H histidine). 
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Oligomer Id: 575      Sequence: A-K-(A-K-((A-Stp)3-A-C)2)2 
δ (ppm) = 1.3-1.8 (m, 75 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2-
CH2-CO-), 3.0 (m, 8 H, βH cysteine), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH2- 
Tp), 3.48-3.54 (m, 144 H, -CH2- Tp), 4.1-4.3 (m, 26 H, αH amino acids). 
 
Oligomer Id: 574      Sequence: A-K-(H-K-((H-Stp)3-H-A)2)2 
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2-
CH2-CO-), 3.1-3.2 (m, 36 H, βH lysine, histidine), 3.2-3.4 (m, 48 H, -CH2- Tp), 3.48-
3.54 (m, 144 H, -CH2- Tp), 4.1-4.3 (m, 8 H, αH lysine, alanine), 4.7 (m, 14 H, αH 
histidine) 7.3 (14 H, imidazole H histidine), 8.6 (14 H, imidazole H histidine). 
 
Oligomer Id: 576      Sequence: A-K-(A-K-((A-Stp)3-A-A)2)2 
δ (ppm) = 1.3-1.8 (m, 87 H, γδεH lysine, -CH3 alanine), 2.5-2.6 (m, 48 H, -CO-CH2-
CH2-CO-), 3.1 (t, 6 H, βH lysine), 3.2-3.4 (m, 48 H, -CH2- Tp), 3.48-3.54 (m, 144 H, -
CH2- Tp), 4.1-4.3 (m, 26 H, αH amino acids). 
 
Oligomer Id: 577      Sequence: A-K-(H-K-((H-Gtt)3-H-C)2)2 
δ (ppm) = 1.3-1.8 (m, 21 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 
3.1-3.2 (m, 42 H, βH lysine, histidine), 3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -
CH2- Tt), 4.1-4.3 (m, 8 H, αH lysine, alanine, cysteine), 4.7 (m, 18 H, αH histidine) 7.3 
(18 H, imidazole H histidine), 8.6 (18 H, imidazole H histidine). 
 
Oligomer Id: 579      Sequence: A-K-(A-K-((A-Gtt)3-A-C)2)2 
δ (ppm) = 1.3-1.8 (m, 75 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.0 (m, 8 H, βH cysteine), 
3.1-3.2 (m, 6 H, βH lysine), 3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -CH2- Tt), 
4.1-4.3 (m, 26 H, αH amino acids). 
 
Oligomer Id: 578      Sequence: A-K-(H-K-((H-Gtt)3-H-A)2)2 
δ (ppm) = 1.3-1.8 (m, 33 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.1-3.2 (m, 42 H, βH 
lysine, histidine), 3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -CH2- Tt), 4.1-4.3 (m, 
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8 H, αH lysine, alanine), 4.7 (m, 18 H, αH histidine) 7.3 (18 H, imidazole H histidine), 
8.6 (18 H, imidazole H histidine). 
 
Oligomer Id: 580      Sequence: A-K-(A-K-((A-Gtt)3-A-A)2)2 
δ (ppm) = 1.3-1.8 (m, 87 H, γδεH lysine, -CH3 alanine), 2.2-2.3 (t, 48 H, -CO-CH2-
CH2-CH2-CO-), 1.8-1.9 (m, 24 H, -CO-CH2-CH2-CH2-CO-), 3.1-3.2 (m, 6 H, βH 
lysine), 3.2-3.3 (m, 48 H, -CH2- Tt), 3.4-3.5 (m, 96 H, -CH2- Tt), 4.1-4.3 (m, 26 H, αH 
amino acids). 
 
Oligomer Id: 582     Sequence: A-K-(K-(K-H-(K-H2)3-K-H-K)2)2 
δ (ppm) = 1.3-1.8 (m, 165 H, γδεH lysine, -CH3 alanine), 2.9-3.0 (m, 54 H, βH lysine), 
3.0-3.3 (m, 64 H, βH histidine), 3.9-4.3 (m, 28 H, αH lysine, alanine), 4.7 (m, 32 H, 
αH histidine) 7.3 (32 H, imidazole H histidine), 8.6 (32 H, imidazole H histidine). 
 
Oligomer Id: 584    Sequence: A-K-(K-(K-H-(K-H2)5-K-H-K)2)2 
δ (ppm) = 1.3-1.8 (m, 213 H, γδεH lysine, -CH3 alanine), 2.9-3.0 (m, 70 H, βH lysine), 
3.0-3.3 (m, 96 H, βH histidine), 3.9-4.3 (m, 36 H, αH lysine, alanine), 4.7 (m, 48 H, 
αH histidine) 7.3 (48 H, imidazole H histidine), 8.6 (48 H, imidazole H histidine). 
7.2.2 Linear cysteine-containing Stp oligomers 
Sequence: C-Stp 
δ (ppm) = 2.5-2.6 (m, 4 H, -CO-CH2-CH2-CO-), 3.0 (m, 2 H, βH cysteine), 3.2-3.4 (m, 
4 H, -CH2- Tp), 3.48-3.54 (m, 12 H, -CH2- Tp), 4.1-4.3 (m, 1 H, αH cysteine). 
 
Sequence: C-Stp2 
δ (ppm) = 2.5-2.6 (m, 8 H, -CO-CH2-CH2-CO-), 3.0 (m, 2 H, βH cysteine), 3.2-3.4 (m, 
8H, -CH2- Tp), 3.48-3.54 (m, 24 H, -CH2- Tp), 4.1-4.3 (m, 1 H, αH cysteine). 
 
Sequence: C-Stp3 
δ (ppm) = 2.5-2.6 (m, 12 H, -CO-CH2-CH2-CO-), 3.0 (m, 2 H, βH cysteine), 3.2-3.4 
(m, 12 H, -CH2- Tp), 3.48-3.54 (m, 36 H, -CH2- Tp), 4.1-4.3 (m, 1 H, αH cysteine). 
 
Sequence: C-Stp4 
δ (ppm) = 2.5-2.6 (m, 16 H, -CO-CH2-CH2-CO-), 3.0 (m, 2 H, βH cysteine), 3.2-3.4 
(m, 16 H, -CH2- Tp), 3.48-3.54 (m, 48 H, -CH2- Tp), 4.1-4.3 (m, 1 H, αH cysteine).  
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Sequence: C-Stp5 
δ (ppm) = 2.5-2.6 (m, 20 H, -CO-CH2-CH2-CO-), 3.0 (m, 2 H, βH cysteine), 3.2-3.4 
(m, 20 H, -CH2- Tp), 3.48-3.54 (m, 60 H, -CH2- Tp), 4.1-4.3 (m, 1 H, αH cysteine).  
7.2.3 PPI conjugates 
Conjugate Id: 418       Sequence: PPI-(C-C-Stp)8 
δ (ppm) = 1.7-2.0 (m, 28 H, -CH2-CH2-CH2- PPI), 2.5-2.6 (m, 32 H, -CO-CH2-CH2-
CO-), 3.0-3.5 (m, 32 H, βH cysteine; m, 32 H, -CH2- Tp; m, 148 H, -CH2- Tp, -CH2-
CH2-CH2- PPI), 4.0-4.5 (m, 16 H, αH amino acids). 
 
Conjugate Id: 427       Sequence: PPI-(C-C-Stp2)8 
δ (ppm) = 1.7-2.0 (m, 28 H, -CH2-CH2-CH2- PPI), 2.5-2.6 (m, 64 H, -CO-CH2-CH2-
CO-), 3.0-3.5 (m, 32 H, βH cysteine; m, 64 H, -CH2- Tp; m, 244 H, -CH2- Tp, -CH2-
CH2-CH2- PPI), 4.0-4.5 (m, 16 H, αH amino acids). 
 
Conjugate Id: 428       Sequence: PPI-(C-C-Stp3)8 
δ (ppm) = 1.7-2.0 (m, 28 H, -CH2-CH2-CH2- PPI), 2.5-2.6 (m, 96 H, -CO-CH2-CH2-
CO-), 3.0-3.5 (m, 32 H, βH cysteine; m, 96 H, -CH2- Tp; m, 340 H, -CH2- Tp, -CH2-
CH2-CH2- PPI), 4.0-4.5 (m, 16 H, αH amino acids). 
 
Conjugate Id: 526       Sequence: PPI-(C-C-Stp5)8 
δ (ppm) = 1.7-2.0 (m, 28 H, -CH2-CH2-CH2- PPI), 2.5-2.6 (m, 160 H, -CO-CH2-CH2-
CO-), 3.0-3.5 (m, 32 H, βH cysteine; m, 160 H, -CH2- Tp; m, 532 H, -CH2- Tp, -CH2-
CH2-CH2- PPI), 4.0-4.5 (m, 16 H, αH amino acids). 
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7.3 Additional analytical Ion Exchange Chromatography 
traces of four-arm unmodified Stp oligomers 
Analytical runs were performed after dialysis in 10 mM HCl on an Äkta Basic HPLC 
system, column: Resource S 1 ml (GE Healthcare). Buffer A: 10 mM HCl. Buffer B: 
10 mM HCl + 3 M NaCl. Flow rate 2 ml/min. Gradient: 2% B to 100% B in 15min. UV 
detection at 214 nm and 280 nm.  
 
286 Stp1      287 Stp2 
   
 
288 Stp3      289 Stp4 
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7.4 AFM images  
AFM images of pDNA polyplexes formed at N/P 12 with (A) Stp-based oligomer 402 
and (B) Sph-based oligomer 519. (C) Particles formed with Gtt-based oligomer 494 
did not form particles detectable by AFM.  
pDNA polyplexes were prepared in 20 mM HEPES, pH 7.4 at N/P 12. After 30 min 
incubation, samples were diluted 1:10 in 20 mM HEPES buffer pH 7.4 and 10µl of the 
dilution was pipetted onto a freshly cleaved mica surface. Samples were imaged in 
the tapping mode on a Multimode VIII AFM (Bruker AXS, Santa Barbara, USA). 
Experiments were performed together with Max Scheible, Department of Physics at 
ZNN/WSI, Biomolecular Systems and Bionanotechnology, TU Munich, Germany. 
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7.5 Additional particle size and zeta potential 
measurements 
7.5.1 Five-arm oligomers after complexation with pDNA at N/P 12.  
 
7.5.2 Size and zeta potential of siRNA Polyplexes.  
Complexation of siRNA with four-arm oligomers at N/P 12. 
 
 
 
Complexation of siRNA with five-arm oligomers at N/P 12.  
 
n.d. not detectable 
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7.6 Abbreviations 
ATP  Adenosine triphosphate 
BCNP Boc-Cys(NPys)-OH 
Boc tert-Butyloxycarbonyl 
CMPI 2-Chloro-1-methylpyridinium iodide 
CMV  Cytomegalovirus 
Da Dalton 
DCM Dichloromethane 
DCU Dicyclohexylurea 
DIPEA  Diisopropylethylamine 
DLS  Dynamic light scattering 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNTB 5,5'-dithiobis-2-nitrobenzoic acid (Ellman’s reagent) 
DTT Dithiothreitol 
eGFP Enhanced green fluorescent protein 
EPR  Enhanced permeability and retention 
EtBr Ethidium bromide 
FBS  Foetal bovine serum 
Fmoc 9-Fluorenylmethyloxycarbonyl 
GSH  Glutathione 
Gtt Glutaroyl-triethylentetraamine 
HBG  HEPES-buffered glucose 
HEPES  N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid) 
HOBt 1-Hydroxybenzotriazol 
IEX Ion exchange 
LL Low load 
linPEI  Linear polyethylenimine  
Luc  Luciferase 
MALDI Matrix assisted laser desorption ionization mass spectrometry 
MES 2-(N-morpholino)ethanesulfonic acid 
MTT  Methylthiazoletetrazolium 
Mw Molecular weight 
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MWCO Molecular weight cut-off 
1H-NMR  Proton nuclear magnetic resonance 
NPys 3-Nitro-2-pyridinesulfenyl 
N/P-ratio  Molar ratio of protonable nitrogens to phosphates  
PBS  Phosphate-buffered saline 
pDNA  Plasmid deoxyribonucleic acid 
pEGFPLuc  Plasmid encoding for luciferase under control of the EGFP 
promoter/enhancer 
PEI Polyethylenimine 
Pfp Pentafluorophenol 
Pip Piperidine 
PPI Polypropylenimine 
PyBOP®  Benzotriazol-1-yl-oxytripyrrolidinophosphonium-hexafluorophosphate 
RBF Round-bottom flask 
RISC  RNA-induced silencing complex 
RLU  Relative light units 
RNA  Ribonucleic acid 
RNAi RNA interference 
RP-HPLC Reversed-Phase High-performance liquid chromatography 
RT  Room temperature 
SAR Structure-activity relationship 
SEC  Size exclusion chromatography 
siRNA  Small interfering RNA 
Sph Succinyl-pentaethylenhexamine 
SPS Solid-phase synthesis 
Stp Succinoyl-tetraethylenpentamine 
Succ Succinoyl 
TCEP  Tris(2-carboxyethyl) phosphine 
TFA Trifluoroacetic acid 
TIS Triisopropylsilane 
TLC Thin layer chromatography 
Trt Trityl 
UV-VIS Ultraviolett-Visible spectroscopy 
w/w  Weight to weight ratio (e.g. of conjugate to nucleic acid) 
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7.7 Publications 
7.7.1 Original papers 
Schaffert, David; Troiber, Christina; Salcher, Eveline E.; Fröhlich, Thomas; Martin, 
Irene; Badgujar, Naresh; Dohmen, Christian; Edinger, Daniel; Kläger, Raphaela; 
Maiwald, Gelja; Farkasova, Katarina; Seeber, Silke; Jahn-Hofmann, Kerstin; 
Hadwiger, Philipp; Wagner, Ernst: Solid-phase synthesized sequence-defined t-
shape, i-shape and u-shape polymers for pDNA and siRNA delivery, Angewandte 
Chemie International Edition (2011), 50, 8986-8989 
 
Fröhlich, Thomas; Edinger, Daniel; Kläger, Raphaela; Troiber, Christina; Salcher, 
Edith; Badgujar, Naresh; Martin, Irene; Schaffert, David; Cengizeroglu, Arzu; 
Hadwiger, Philipp; Vornlocher, Hans-Peter; Wagner, Ernst: Structure-activity 
relationships of siRNA carriers based on sequence-defined oligo (ethane amino) 
amides, Journal of Controlled Release (2012), 160, 532-541 
 
Salcher, Eveline E.; Kos, Petra; Fröhlich, Thomas; Badgujar, Naresh; Scheible, Max; 
Wagner, Ernst:  Sequence-defined Four-arm Oligo(ethanamino)amides for pDNA and 
siRNA Delivery: Impact of Building Blocks on Efficacy, Journal of Controlled Release 
(2012), Journal of Controlled Release (2012), 164, 380-386 
 
Lächelt, Ulrich; Kos, Petra; Mickler, Frauke M.; Salcher, Eveline E.; Rödl, Wolfgang; 
Badgujar, Naresh; Bräuchle, Christoph; Wagner, Ernst (2013) Fine-tuning of proton 
sponges by precise diaminoethanes and histidines in pDNA polyplexes. Submitted. 
 
Kos, Petra; Scholz, Claudia; Salcher, Eveline E.; Herrmann, Annika; Wagner, Ernst:  
Gene transfer with sequence-defined oligo(ethanamino)amides bioreducibly attached 
to a propylenimine dendrimer core. Submitted. 
7.7.2 Book chapters 
E. Salcher and E. Wagner: Chemically programmed polymers for targeted DNA and 
siRNA transfection, Topics in Current Chemistry (2010); 296:227-249 
 
E. Salcher and E. Wagner: Nanoencapsulation of oligonucleotides for therapeutic 
use, Nucleic Acids Nanotechnology, Manuscript submitted 
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7.7.3 Poster presentation 
E. Salcher, D. Schaffert, Thomas Fröhlich, P. Kos, E. Wagner: Solid-Phase 
Supported Synthesis of Branched Cationic Polymers for Gene Delivery, CeNS 
Workshop, Venice, Italy, September 2011 
 
7.7.4 Oral presentation 
E. Salcher, D. Schaffert, Thomas Fröhlich, P. Kos, E. Wagner: Solid-phase Synthesis 
of Precise Branched Polymers for Gene Delivery, Doktorandenseminar Fakultät für 
Chemie und Pharmazie, LMU München, Munich, April 2011 
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